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1. Abstract 
Memory B cells and antibodies are major mediators of protective immune responses 
yet the mechanisms of their induction, maintenance and memory reactivation are 
poorly understood. Studies of secondary immunizations or recurrent infection cours-
es, e.g. for tetanus and influenza, are abundantly available, while comparable de-
tailed data with respect to primary immunizations in humans are so far lacking. 
Furthermore, as recall responses require memory B cell (mBC) maintenance, conse-
quently, the question arises how and where this B cell memory is maintained. 
To address this, in the first part of this study the characteristics of a human primary 
and secondary immune response to Keyhole Limpet Hemocyanin (KLH) was com-
prehensively examined, as an example for the principle plasma cell and mBC induc-
tion and reactivation of the latter. In the second part of this thesis mBC maintenance 
was investigated by a systematic analysis of mBC presence, frequency and pheno-
type within different lymphoid organs. 
Primary parenteral KLH immunization resulted in a pronounced IgA response on both 
the serum and cellular level whereby discordances between both were detected, 
suggesting different restrictions for the humoral and B cellular layer. The unexpected 
simultaneous presence of low and highly mutated circulating KLH-specific (KLHspec) 
plasmablasts (PB) 2-3 weeks after vaccination suggested not only the recruitment of 
naïve B cells but also of presumably cross-reactive mBC. Further detailed analysis of 
the clonal composition of blood KLHspec primary PB, steady state mBC and PB 7 
days upon secondary immunization revealed only little overlap of these three B cell 
repertoires suggesting that the respective progenitor cells underlay distinct recruit-
ment and selection mechanisms.  
With respect to the organ distribution of human mBC, the spleen was identified to 
harbor most mBC followed by tonsils, bone marrow (BM) and circulating mBC within 
the blood. All mBC pools exhibited a largely comparable phenotype. Yet interestingly, 
we found only tonsillar mBC to express CD69, while they rested in terms of prolifera-
tion comparably to mBC from the other tissues. This suggests that tonsillar mBC 
could constitute a tissue resident population. In line, tonsillectomy did not affect the 
circulating mBC pool. 
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The observations described allow insights into hitherto unknown potential mecha-
nisms behind primary immune responses, i.e. prominent IgA induction by parenteral 
challenge and inclusion of cross-reactive mBC. The so far unclear regulatory players 
involved deserve future investigation as such knowledge may be crucial for therapeu-
tic interventions in immune system disorders. 
Furthermore, we found phenotypic similar mBC to distribute between lymphoid or-
gans and to continuously recirculate in peripheral blood indicative of their potential 
permanent screening activities which differs strikingly to the resident plasma cells in 
the BM. Thus, the results suggest that quiescent human mBC do not require dedicat-
ed niches for their principle survival but rather represent a dynamic repertoire.  
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2. Zusammenfassung 
Gedächtnis-B-Zellen und Plasmazellen sind essentielle Komponenten der protektiven 
Immunität. Die Mechanismen ihrer Induktion, ihres Überlebens und der Gedächtnis-
B-Zellreaktivierung sind allerding bisher nur unvollständig verstanden. Detaillierte 
Untersuchungen zu sekundären Immunantworten oder Immunantworten zu wieder-
kehrenden Infektionen, wie zum Beispiel zu Tetanus oder Influenza Infektionen, gibt 
es viele im Menschen. Jedoch gibt es keine vergleichbar detaillierten Daten zu pri-
mären Immunantworten. Weiterhin setzen sekundäre B-Zellimmunantworten das 
Vorhandensein von Gedächtnis-B-Zellen voraus, woraus sich die logische Frage 
ergibt, wo und wie diese Zellen in der Zwischenzeit überleben. 
Um unser Wissen diesbezüglich zu erweitern, wurden im ersten Teil der vorliegenden 
Arbeit Charakteristika von Primär- und Sekundärimmunantworten nach Immunisie-
rung mit Keyhole Limpet Hemocyanin (KLH) untersucht. Im zweiten Teil dieser Arbeit 
wurden die Überlebensbedingungen der Gedächtnis-B-Zellen genauer untersucht. 
Dazu wurden in einem systematischen Ansatz die Frequenzen der Gedächtnis-B-
Zellen sowie deren Phänotyp in verschiedenen lymphatischen Geweben erhoben. 
Die primäre parenterale KLH Immunisierung führte zu einer deutlichen IgA Induktion 
auf serologischer und zellulärer Ebene. Beim Vergleich beider Kompartimente erga-
ben sich jedoch quantitative Unterschiede der IgG zu IgA Verhältnisse, was auf eine 
unterschiedliche Regulierung hinweist. Die unerwartete Präsenz von hochmutierten 
Plasmablasten parallel zu un- bis wenig mutierten Plasmablasten 2-3 Wochen nach 
der primären Immunisierung deutete darauf hin, dass in diese Immunantwort nicht 
nur naive B-Zellen rekrutiert wurden, sondern auch Gedächtnis-B-Zellen, die wahr-
scheinlich mit dem KLH kreuzreagierten. Weiterhin ergab die Analyse der klonalen 
Verwandtschaften von primären Plasmablasten, Gedächtnis-B-Zellen und den Plas-
mablasten induziert durch die Sekundärimmunisierung, dass es nur wenige Über-
schneidungen gab. Dies deutet darauf hin, dass die Zellen, bzw. deren Vorläufer bei 
Primär- und Sekundärimmunisierung individuellen Rekrutierungs- und Selektionsme-
chanismen ausgesetzt waren. 
Die Untersuchungen der Gedächtnis-B-Zellverteilung in verschiedenen lymphati-
schen Geweben ergab, dass die meisten in der Milz, gefolgt von Tonsillen und Kno-
chenmark zu finden waren und der zirkulierende Gedächtnis-B-Zellpool nur einen 
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kleinen Teil der Gesamtmenge ausmachte. Trotz des unterschiedlichen Vorkommens 
von Gedächtnis-B-Zellen fanden sich nur wenige phänotypische Unterschiede. Einer 
davon war die CD69 Expression auf tonsillären Gedächtnis-B-Zellen, die sich jedoch 
nicht teilten. Diese Kombination deutet darauf hin, dass tonsilläre Gedächtnis-B-
Zellen tatsächlich sessil sein könnten und somit nicht am rezirkulierenden Gedächt-
nis-B-Zellpool teilhaben würden. Konsistent mit dieser Schlussfolgerung ist auch die 
Beobachtung, dass Tonsillektomien keinen quantitativen Einfluss auf den zirkulieren-
den Gedächtnis-B-Zellpool hatten. 
Die in dieser Arbeit erhaltenen Ergebnisse bieten neue Erkenntnisse über bisher un-
beschriebene Mechanismen von humanen primären Immunantworten. Zum einen 
wurde demonstriert, dass parenterale Impfungen IgA Antikörper induzieren können. 
Zum anderen scheinen an solchen primären Immunantworten kreuzreaktive Ge-
dächtnis-B-Zellen teilzunehmen. Es bleibt zu klären, wie die Reaktivierung dieser 
Gedächtnis-B-Zellen reguliert ist. Dieses Wissen ist durchaus für die Therapie und 
das Verständnis von Erkrankungen des Immunsystems, wie z.B. von Autoimmunität, 
von Bedeutung. 
Des Weiteren zeigen die Ergebnisse, dass sich phänotypisch weitgehend gleiche 
Gedächtnis-B-Zellen in unterschiedlicher Quantität in verschiedenen lymphatischen 
Geweben verteilen sowie auch kontinuierlich im Blut zirkulieren. Dieses patrouillie-
rende Verhalten der Gedächtnis-B-Zellen ist ein deutlicher Unterschied zu den Ni-
schen-abhängigen Plasmazellen. Die Ergebnisse deuten weitestgehend darauf hin, 
dass Gedächtnis-B-Zellen nicht auf derartige Nischen angewiesen sind und ein dy-
namisches Repertoire darstellen. 
 
Introduction 
5 
 
3. Introduction 
The principle of immunity has already been described 430 BC by Thucydides. It 
arose from the original observation that when a person suffered from a disease once, 
such as the plaque for example, this person was in principle never attacked a second 
time or if, only suffered a mild course, even though that person still had contact to 
other infectious plaque patients (1). Thus, the person exhibited a certain non-
susceptibility to the disease. 
We now know that the key to this perceivable immunity is the primary infection itself 
and the survival of it, as our immune system fights off the pathogen and establishes 
an immunologic memory. We have even learned to use that principle in a controlled 
safe setting, i.e. vaccination. The vaccinee is usually inoculated with an attenuated 
pathogen or a detoxified or inactivated protein to which the immune system reacts, 
without the risk of permanent damages, and establishes immunological memory. This 
memory then protects the individual during future infections from the symptoms or a 
potentially fatal result. Vaccines led to the eradication of some widespread diseases, 
e.g. smallpox or tetanus, but the successful development of new vaccines proves 
difficult as often the induction of protective serum antibodies is inefficient. Examples 
of such cases are infectious diseases such as influenza or HIV or immune responses 
in immunocompromised individuals (2, 3). Although we have an overall idea of under-
lying mechanisms and processes of immune responses, many aspects of the induc-
tion, maintenance and reactivation of human immunological memory remain unclear. 
Yet such knowledge is of importance for the design of new vaccines and disease in-
tervention strategies. 
3.1 The vertebrate immune system 
The immune system, consisting of organs, tissues, cellular and soluble components, 
is able to rapidly sense and respond to a vast array of invading pathogens and sub-
stances but can also eliminate own degenerated cells to maintain the bodies integri-
ty. Thereby its arsenal contains on the one hand cells, e.g. dendritic cells (DC), 
macrophages, granulocytes and natural killer cells, and receptors (pattern recognition 
receptors (PRR)) that belong to the innate immune system, which recognize a de-
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fined and restricted amount of pathogen patterns (pathogen-associated molecular 
patterns (PAMP)). This arm of the immune system triggers an immediate response to 
pathogens like bacteria, fungi, parasites and viruses. This response may already lead 
to elimination of the pathogen but moreover yields cytokine secretion and presenta-
tion of peptides from the pathogen’s protein antigens in major histocompatibility com-
plex (MHC) molecules by specialized phagocytes, collectively known as antigen-
presenting cells, which include DC. This step marks the critical interface between the 
innate and the adaptive immune system, the latter which constitutes the other arm of 
the immune system.  
The adaptive immune system consists of B- and T lymphocytes (B and T cells) carry-
ing highly diverse specialized antigen recognition receptors on their cell surfaces. 
These receptors are capable of recognizing an almost unlimited variety of antigens, 
but in a specific fashion. Thereby, thymus-dependent cells (T cells) carry the T cell 
receptor (TCR) that recognizes the complex of a peptide:MHC molecule and confer 
classically either cellular immunity, i.e. they mount responses to intracellular patho-
gens or orchestrate a subsequent immune response. 
The specialized antigen receptor of B cells (originally from Bursa fabricii (birds) de-
rived cells) is the B cell receptor (BCR). It directly recognizes unprocessed extracellu-
lar epitopes that in concert with other signals activate the B cells. This response is 
referred to as humoral immunity. The B cells can either terminally differentiate into 
plasma cells (PC) which secrete the BCR in its soluble form, known as antibodies, or 
into memory B cells (mBC) or other effector B cells.  
An important feature and hallmark of the adaptive immune system is its ability to 
adapt its measures of recognizing or responding towards a pathogen, e.g. the B and 
T cells can adjust cytokine secretion patterns, lower their activation thresholds or, 
exclusive to B cells, increase their antigen receptor affinity and alter its effector func-
tion. Finally, generation of immunological memory is also a distinctive feature of the 
adaptive immune system enabling a faster and stronger response upon pathogen re-
encounter as well as establishment of protective antibody titers which potentially di-
rectly counteract the effective infection of the host at all.  
These natural properties of the adaptive immune system are the underlying mecha-
nisms to long-term protection, which is utilized by vaccination strategies. However, 
most successful vaccines have been found empirically with no or only little immuno-
logical insight and often confer protection by induction of humoral responses. Re-
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flected in our current failure to develop new vaccines and treatments to immunodefi-
ciencies and autoimmune diseases, gaining a deeper understanding of the formation 
and maintenance of immunological memory is clearly of importance. 
3.2 B cells and the humoral immune response 
3.2.1 The B cell receptor 
Each B cell carries a unique membrane bound BCR that is in its secreted form re-
ferred to as antibody or often also simply as immunoglobulin (Ig). In humans, this Ig 
is a tetrameric molecule consisting of two identical Ig heavy chains (IgH) and two 
identical Ig light chains (IgL). Both, IgH and IgL, consist of several homologous do-
mains of approximately 110 amino acids each. IgL consist of two, IgH of four to five 
of such globular Ig domains, depending on the isotype for the latter. The domains of 
the IgH and IgL chains are covalently linked by disulfide bonds which together with 
non-covalent interactions lead to the typical Y-shape three dimensional structure of 
an antibody (Figure 3-1). At the aminoterminal domain both chains possess a varia-
ble region and the adjacent part stretching towards the carboxyterminal end consti-
tutes the constant region.  
 
Figure 3-1 Schematic structure of a BCR molecule.  
A BCR complex, i.e. membrane bound BCR with its accessory molecules Igα and Igβ. Indicated are 
the variable heavy (VH) and variable light (VL) regions as well as the constant light (CL) and constant 
heavy (CH) regions, for the latter subdivided in domains 1-3, as can be found e.g. in an IgG. TM: trans- 
membrane domain. B Three dimensional structure of a secreted Ig. Indicated in orange, pink and pur-
ple are the loops comprising the complementary determining regions (CDR) on the right side. The 3D 
structure has been modified from the pdb file 1igt (www.pdb.org). 
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Functionally, the variable regions of the IgH and IgL contain the antigen binding re-
gion. Structurally, they consist of four framework regions (FWR1-4), which are β-folds 
providing the backbone and maintain the Ig’s characteristic barrel like shape. These 
are intervened in a non-consecutive fashion by three complementary determining 
regions (CDR), termed CDR1, CDR2 and CDR3. In the tertiary structure, the CDR 
form loops that stick out of the barrel and constitute the antigen-binding site (Figure 
3-1 B). Contact of the Ig to the antigen occurs through non-covalent interactions with 
complementary structures on the antigen, termed epitopes.  
The constant regions, generally denoted by greek letters, of the IgL chains are 
termed κ and λ. A functional difference between them is currently not known. For the 
IgH chain, there are five different main constant region classes encoded by the 
µ, δ, γ, α and ε gene segments, resulting in IgM, IgD, IgG, IgA and IgE Ig isotypes, 
respectively (4). Further distinction of isotype subclasses exists for IgG, i.e. IgG1 to 
IgG4, and for IgA, namely IgA1 and IgA2. For the membrane bound form of the Ig, a 
transmembrane domain anchors the BCR into the cell membrane leaving a short cy-
toplasmic tail. For signal transmission, the accessory molecules Igα and Igβ are re-
quired which all together form the BCR complex.  
This complex has two major functions. Firstly, signal transduction upon appropriate 
antigenic contact. This leads to different outcomes regarding the B cells’ survival, 
proliferation and differentiation, depending on the subsequent signals and interac-
tions with other cells. Secondly, antigen-BCR binding leads to internalization of the 
BCR-antigen-complex for subsequent antigen processing and presentation of pep-
tides in MHC class II molecules. This is crucial for communication with other cells 
which potentially provide survival signals during immune responses. 
In its soluble form, the differences of the IgH isotype classes with regard to their dif-
ferent composition, biological properties, location and their resulting mode of action, 
which is referred to as effector function, become of major functional importance. In 
short, antibodies can neutralize the pathogen, mark it for degradation by phagocyto-
sis (opsonization) or complement, or activate other effector cells, inducing more or 
less inflammatory responses in consequence. While all isotypes can be found se-
creted as monomers, IgM and IgA can for pentamers and dimers, respectively. 
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3.2.2 Generation of the primary B cell repertoire diversity 
The variable regions of the expressed BCR are not present as such in the germ line 
(5). Instead, the BCR is assembled during B cell development in a series from site-
specific recombination events termed V(D)J recombination (illustrated in Figure 3-2), 
taking place in the bone marrow (BM) in human adults. This somatic rearrangement 
process is the central feature of the B (and T) cells’ ability to generate a highly di-
verse set of antigen receptors.  
The human IGH locus is located on chromosome 14 (14q32.33) and comprises mul-
tigene families of variable heavy (VH), diversity (D) and joining heavy (JH) segments 
(6, 7). The VH gene cluster consists of 123 VH segments of which 44 are classified as 
functional and can theoretically be expressed (8). These VH segments were subdi-
vided into seven distinct families based on their sequence homology. The JH gene 
segment cluster contains six functional JH segments (9) and the D gene segment 
cluster contains 27 functional segments (10). The IGH CH locus comprises 11 genes 
of which two are pseudogenes (8). The human CH genes for secretory Ig forms are 
composed of three (γ and α) or four (µ and ε) exons.  
 
Figure 3-2 B cell Ig chain gene recombination and assembly.  
Schematic illustration of the process of V(D)J recombination for IgL (left) and IgH (right) chain. Critical 
for the joining process during V(D)J recombination are the recombination signal sequences (RSS) 
which are directly adjacent to every segment’s 3’ and/or 5’ coding region. RSS consist of a highly con-
served heptamer (CACAGTG) and a less conserved nonamer (ACAAAAACC), interspersed with a 
non-conserved region known as the spacer, which is either 12 or 23 nucleotides long. During the re-
combination process, only gene segments flanked by an RSS with a 12-base pair spacer can be 
joined to one flanked by a 23 base pair spacer RSS, ensuring that V(D)J recombination is restricted to 
events that are biologically productive.  
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The hydrophobic transmembrane and short cytoplasmic segments for the BCR are 
encoded by one (α) or two (others) exons. Expression of either the secretory or 
membrane Ig form is controlled by alternative splicing. The VH and CH loci are physi-
cally linked on the chromosome in the order of 5’-VH-DH-JH-CH-3’.  
Human κ and λ chain loci are located at 2p11.2 and 22q11.2, respectively, and com-
prise 40 and 30 Vκ and Vλ segments, respectively, and 5 Jκ and 4 Jλ, respectively 
and one CL segment each (11, 12). 
The underlying processes of V(D)J recombination and the factors involved have been 
extensively reviewed elsewhere (13-16). To shortly summarize, B cells develop from 
hematopoietic stem cells through well-defined stages. For the IgH and IgL chain to-
gether three major developmental stages were defined. In the first stage, lymphoid 
progenitor cells rearrange a D to a JH segment, on both loci, to become a pro B cell 
followed by a second rearrangement joining an upstream VH segment to the assem-
bled D-JH region, only on one locus first. If this is productive, then the second locus is 
not further rearranged. Otherwise, rearrangement on the other locus occurs which 
however silences the expression of the first locus. The principle that B cells express 
only one variable region combination is called allelic exclusion (17). The productive 
VHDJH rearrangement is joined to a µ chain and expressed on the B cell precursor’s 
surface as preBCR. If this rearrangement is functional, the B cell precursor enters the 
next phase, i.e. pre-B cell stage, in which the cell divides a few times, exits the cell 
cycle and subsequently rearranges the IGL locus according to the same principles as 
for the IGH chain with the exception that no D segments exist (Figure 3-2). Thereby, 
the κ gene locus is rearranged up to several times first and if finally non-productive, 
the λ chain locus is rearranged leading eventually to expression of a functional BCR 
or otherwise to termination of the cell. Again, the B cell expresses only one type of 
IgL chain, termed isotype exclusion. 
The pure combinatorial diversity from this process accounts theoretically for 2.3x106 
different BCR receptors. However, in addition to this diversity, during the V(D)J re-
combination itself the diversity is further increased by joining the gene segments im-
precisely including addition of non-templated and palindromic nucleotides to the open 
DNA ends. Therefore, this junctional diversity is located and actually builds the so 
termed CDR3 regions which are the most variable of all CDR regions and are also 
considered as the major determinants of the specific interaction between BCR and 
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antigen. Furthermore, each single BCR or antibody can be uniquely identified by its 
CDR3 sequences, largely defining a B cell clone.  
At the end of this developmental process stands an immature B cell. At this point, B 
cells with an auto-reactive BCR are largely negatively selected by either undergoing 
apoptosis (clonal deletion) (18), becoming unresponsive (anergic) (19) or re-entering 
into the rearrangement process (receptor editing) (20). B cells that pass this so 
termed central tolerance checkpoint, in mice approximately 10% of the generated 
clones (21), leave the BM and migrate to the spleen where they undergo further se-
lection and maturation (22) into functional naïve B cells that subsequently recirculate 
and screen the periphery for pathogens/antigens.   
3.2.3 Primary humoral response 
A primary humoral immune response is mounted on the occasion the eliciting antigen 
is encountered for the first time (illustrated in Figure 3-3 B). B cell responses are 
classified as either T cell-dependent (TD) or T cell-independent (TI) largely deter-
mined by the nature of the antigen. TD response-eliciting antigens are usually pro-
teins which engage the BCR in a highly specific fashion and which can be presented 
in MHC class II molecules. For initiation of division and differentiation of the specific B 
cells additional signals are required and these include the interaction of the specific B 
cells with T cells. TD responses generally result in generation of memory. Such re-
sponses and will be elaborated in this section. 
Humoral responses to TI antigens, as intended by the name, do not require T cell 
help for their induction. Such antigens can be either of a mitogenic nature, e.g. CpG 
or lipopolysaccharide, which cause a polyclonal activation of B cells, i.e. independent 
of the BCR specificities. Or TI antigens can be large polymeric or aggregated pro-
teins, or capsular polysaccharides that cross-link specific BCR and thus activate the 
B cells without requirement of additional signals. TI responses generally do not gen-
erate memory and are beyond the scope of this study.  
At the beginning of an adaptive TD response stands the activation of the innate im-
mune system. Most pathogens carry PAMP which can be bound by PRR on innate 
immune cells. Of importance for initiation of adaptive immune responses are the up-
take and presentation of the pathogen by antigen-presenting cells, e.g. DC. Specifi-
cally DC carry a vast array of PRR enabling them to sense a wide range of 
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pathogens. In such a case, the activated DC take up the pathogen, process it and 
migrate to draining lymph nodes (LN) or spleen. Here they seek contact with T cells 
and present peptides of the pathogen via their MHC class II molecules (23). In prima-
ry cellular responses the process of antigen presentation is predominantly, if not ex-
clusively, mediated through DC. Naïve CD4pos T cells with a specific TCR can 
recognize this peptide:MHC class II complex and become activated, proliferate and 
differentiate into CD4pos effector T cells. At the same time, recirculating naïve B cells 
screen the periphery, including secondary lymphoid organs, for matching antigens. 
Eventually they encounter also the pathogen or pathogen subunits. Binding of their 
specific BCR causes activation of the respective cells but also antigen uptake. The 
ingested antigen is then processed and presented as peptide:MHC class II complex-
es on their surface. Subsequent complete activation of these B cells does only occur 
if they encounter an activated cognate CD4pos effector T cell, usually happening at 
the T cell:B cell border in a secondary lymphoid organ (24, 25) to which the B cells 
and T cells locate in a chemokine-dependent manner (26). Most important interac-
tions here include engagement of CD40 on B cells by CD40L, presented by the acti-
vated T cells, interaction of the B cells’ peptide:MHC class II complex with the TCR 
and CD4, provision of CD80 and CD86 by the B cells to the T cells (27), inducible 
costimulator (ICOS)- inducible costimulator ligand (ICOSL) interaction and secretion 
of IL4 and IL21 by the T cells (28-32), collectively referred to as co-stimulatory sig-
nals. The completely activated B cells proliferate vigorously. They then either differ-
entiate into extra-follicular PC, secreting unmutated and low affinity, mostly IgM, 
antibodies which can be detected in the serum (Figure 3-3 A and B). These PC are 
generated early during primary immune responses, i.e. after a couple of days (33), 
and are typically short-lived and of a non-migratory nature (34, 35).  
Alternatively, the activated B cells migrate to a B cell follicle and become germinal 
centre (GC) founder B cells (33). These keep dividing subsequently generating a GC 
while they push the remaining non-dividing naïve B cells aside which then form the 
mantle zone. Plasmablasts (PB)/PC arising from the GC reaction are the source of 
the later detectable, higher affine class-switched antibodies. 
Albeit B cells and T cells recognize quite distinct structures of the same molecule de-
rived from a pathogen, the mechanism that only T and B cells with a specific receptor 
become activated and expanded is commonly referred to as clonal selection. Thus, 
from the existing receptor repertoires, which for human B cells could theoretically 
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comprise up to 1011 individual clones (36), only a small fraction of cells/receptors is 
engaged by any antigen. Studies from primary human responses are not available in 
this regard, but studies investigating secondary antigen-specific B cell repertoires, 
e.g. BCR specific to tetanus toxoid (TT), estimated these specific repertoires to range 
between 30- 200 clones (37-39). 
3.2.4 The GC reaction –  
antigen-dependent B cell repertoire diversification 
Antibodies produced initially in a systemic TD primary immune response are of low 
affinity and mostly of the IgM isotype, while antibodies produced later during that re-
sponse are of higher affinity and comprise mainly switched isotypes, i.e. IgG antibod-
ies (40) (Figure 3-3). The molecular analysis of IgL and IgH chains of B cells from 
mice undergoing TD immunization has further shown that in parallel somatic point 
mutations are introduced into the rearranged variable regions (41-47), responsible for 
the affinity increase. The underlying mechanism of these changes is the second ma-
jor mechanism contributing to the B cell Ig repertoire’s diversity, termed affinity matu-
ration and occurs in a GC.  
GC are compartmentalized into two zones: a dark zone (DZ) and a light zone (LZ) 
(48, 49) (illustrated in Figure 3-3 B). The dark zone consists almost exclusively of 
densely-packed proliferating B cells, named centroblasts (CB). Human CB diversify 
their Ig variable genes by somatic hypermutation (SHM), a process that modifies the 
Ig variable regions by introducing mostly single nucleotide exchanges but also small 
deletions and duplications (50, 51). The process of affinity maturation is catalyzed by 
the enzyme activation induced deaminase (AID) targeting the rearranged variable 
and constant Ig loci. This enzyme is critical to SHM but also to class switch recombi-
nation (CSR) (52).  
Basically, the AID removes the amino group from a cytosine transforming it into a 
uracil, thereby creating a DNA mismatch. In the GC environment different complex 
(error prone) DNA repair mechanisms are then initiated leading either to a mutation 
or repair of the DNA lesion, which has been reviewed elsewhere (53-57).  
As an indicator of T-B cell interactions, it has been shown that SHM are specifically 
targeted to mutation hotspots, e.g. the sequence motives RGYW/WRCY (R= purine, 
Y= pyrimidine and W= A/T) (53). Furthermore, SHM introduced during GC reactions 
seem to have a non-random pattern, with replacement (R) mutations found to be 
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overrepresented within the CDR and underrepresented within the FWR whereas the 
opposite is true for silent (S) mutations. This property has been assigned to the se-
lection processes specifically occurring in the GC environment. Yet, the pure intro-
duced SHM in the Ig variable regions only randomly change the affinity of the BCR 
and pattern of mutations.  
An adjacent stringent selection process ensures that only those B cells expressing 
the highest affinity BCR survive. This occurs within the LZ to which CB migrate and 
give rise to smaller, non-dividing centrocytes (CC) which are then intermingled within 
a mesh of follicular DC (FDC), macrophages and few T follicular helper cells (TFH). 
Survival of CC is dependent on interaction with these cells (58). In short, FDC pre-
sent antigen in the form of immune complexes on their surfaces (59). The CC re-
expresses the diversified BCR and if the affinity of it is appropriate in a competitive 
fashion it gets access to the antigen, binds and internalizes it. The antigen is then 
again processed and presented in peptide:MHC class II complexes. The CC then 
competes for TFH survival signals. Current models suggest that the limited number of 
TFH in the GC creates a highly competitive environment with only the highest affinity 
B cells receiving sufficient T cell help (60). In consequence, the modified BCR can be 
positively selected for improved binding. CC producing an unfavorable BCR undergo 
apoptosis.  
A further modification of the BCR within the LZ is the CSR by which B cells irreversi-
bly switch their Ig isotype class expression, initially from IgM and IgD to other clas-
ses. This process depends on CD40-CD40L ligation as well as cytokines determining 
the resulting isotype (61).  
Positively selected B cells either migrate back into the DZ to undergo further rounds 
of affinity maturation (26), leading to increasingly higher affinity BCR over time (43, 
62). Or, B cells leave the GC. B cells emigrating from the GC reaction can either be-
come mBC or PB and eventually PC. The mechanisms contributing to the B cell’s 
fate decision and the time point of their fate determination are incompletely under-
stood.  
Yet, it is widely accepted that post-GC PB migrate via the blood to the BM. Antigen-
specific primary PB were found to peak in blood not before day 10 upon primary im-
munization (63). In the BM, they presumably compete with resident long-lived PC for 
hypothetical survival niches, to become resident long-lived PC themselves. As long-
lived PC they secrete protective antibodies over decades (64-68). In contrast, mBC 
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are functionally inactive, mostly quiescent, long-lived cells (69) that in part at least 
circulate through the blood and lymph (70).  
After resolution of the response the immune system exhibits an altered state of its 
adaptive immune cells specific for the challenging antigen, known as memory. Thus, 
immunological memory is the persistence of resting memory T cell subsets, resting 
affinity maturated mBC and long-lived PC. 
3.2.5 The secondary humoral response 
B cell re-encounter with an anamnestic TD antigen triggers a secondary antibody 
response. Generally, in contrast to the primary response, secondary immune re-
sponses exhibit a faster onset, are of higher magnitude and more sophisticated re-
garding the array of effector functions (summary see Table 3-1 and Figure 3-3). This 
is a direct consequence of the generation of mBC and memory T cells during primary 
antigenic exposure. For B cells specifically, there are qualitative differences in the 
nature of the antibodies produced, for they are now predominantly of the IgG or IgA 
isotype class, depending on their site of induction, and of higher affinity than those 
detected during primary immunization. Moreover, during secondary responses, spe-
cific mBC are capable to present antigen peptides efficiently to T cells (71-73) induc-
ing their activation whereas naïve B cells do not appear to possess that property.  
 
Table 3-1 Features of primary and secondary humoral responses (adapted from Ademokun and 
Dunn Walters (74) and Janeway's immunobiology (75)). 
Feature Primary response Secondary response 
Antigen presentation Mainly non-B cells, rather DC mBC increasingly involved 
Responding B cell Naïve  Memory 
Frequency of antigen-
specific B cells 
1:104 – 1:105 1:102-1:103 
Inducing antigens All antigens (TI and TD) Protein antigens 
Antigen dose required Relatively high dose; optimally 
with adjuvant 
Relatively low doses, works 
without adjuvant 
Lag phase 4-7 days 2-5 days 
SHM None to low  High 
Antibody isotype class Predominantly IgM in the early 
response, later switched isotypes 
Predominantly IgG or IgA (de-
pending on site of induction) 
Antibody affinity Low High 
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Consequently, mBC rapidly generate new antibody-secreting PB (38, 76), which peak 
in peripheral blood with a striking consistency independent of the eliciting antigen or 
pathogen between days 6-8 (77). These PB likely again migrate to the BM extruding 
some of the resident long-lived PC (78). Thus recall responses should lead to a con-
tinuous replenishment and improvement of the protective long-lived PC pool.  
 
 
 
Figure 3-3 Schematic overview of a primary and secondary adaptive humoral response. 
A Left: primary response. After an initial lag phase (time period between antigen (ag A) exposure and 
appearance of specific serum antibodies), specific serum antibodies (Ab) appear, which are predomi-
nantly of the IgM isotype. In the later phase of the primary response class-switched serum antibodies 
appear (mostly IgG in a systemic parenteral response). Right: secondary response. After a very short 
lag phase, a switched isotype dominated and heightened antibody serum response is measurable.  
B Illustration of the serum antibody-underlying primary B cell response. To antigen A-specific naïve B 
cells become activated, proliferate and their descendants either generate antibody-secreting PB/PC 
which are the source of the early IgM serum antibodies. Alternatively, some B cells give rise to a GC 
reaction, which gives rise to affinity maturated and class-switched antibody secreting PB/PC and mBC. 
The PB presumably migrate to their protected niche (e.g. BM) to become long-lived PC. The life style 
and whereabouts of mBC during the memory phase remain unclear. Yet, upon secondary “ag A” con-
tact, mBC mount a memory response which is the reason for the under A illustrated secondary re-
sponse antibody kinetics. DZ: dark zone. LZ: light zone. MZ: Marginal zone. MtZ: mantle zone. FDC: 
follicular dendritic cell. TH: T cell help. 
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The role of GC, whether they are re-initiated and the impact and requirement for T 
cell help in secondary responses is however unclear. With regard to the latter, mBC 
stimulated in vitro can generate PB independent of T cell help (79) whereas T cell 
help in fact suppresses the differentiation of mBC into PB in a CD40L dependent 
manner (80, 81), keeping them in a blastic state which potentially could make them 
prone to become GC founder cells again.  
It remains currently unclear whether mBC or their descendants re-enter GC, however 
the antigen-specific mBC pool appears to repeatedly improve as determined by an 
increasing frequency of SHM from primary to secondary to tertiary responses (62, 82, 
83). But this concept is not undisputed (84).  
Especially for humans, these aspects remains unknown. Although B cell memory re-
sponses were intensively analyzed (38, 39, 77, 85), the identity and properties of the 
antigen-specific B cell repertoire before re-immunization has not been studied. The 
dimensions to which the effector B cell repertoire recalls sequences already em-
ployed during primary immunization and which fraction of the available specific reper-
toire is represented in peripheral blood at all is unknown. In line, it is not possible to 
draw conclusions on diversification and selection processes if only the memory re-
sponse is analyzed. Therefore, detailed studies of primary together with secondary 
responses, focusing on antigen-specific B cells, would potentially deliver such in-
sights but are lacking in humans so far. 
3.2.6 Immunological B cell memory and its maintenance  
Immunological memory is the feature of the adaptive immune system to respond 
more rapidly and effectively to already encountered pathogens. In essence immuno-
logical memory refers to the altered state of the immune system that as a net result 
provides improved passive and active immune protection.  
With regard to the mediating lymphocyte subsets the altered state includes a) higher 
frequency of antigen-specific memory T and B cell subsets in contrast to low fre-
quency of antigen-specific naïve cells, b) the memory cells are antigen-experienced 
and thus functionally superior compared to naïve cells, c) the memory cells exhibit 
extended life spans and d) they exhibit a lower activation threshold compared to the 
naïve lymphocytes.  
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Human B cell memory consist of two major components: reactive mBC and long-lived 
PC (Figure 3-3 B). Long-lived PC preferentially reside in niches in the BM (65) but 
were also identified in spleen (86) and tonsil (87) and appear to depend on survival 
signals delivered from stromal cells and eosinophils (88, 89). Outside of immunization 
or infection PB/PC are only rarely encountered in peripheral blood. In fact, long-lived 
PC are thought to be sentenced to death once they are extruded from their niche. 
In contrast, potential survival niches for mBC and the role of certain organs and fac-
tors in mBC maintenance and functionality remain largely unknown. Yet, their lifestyle 
surely differs to that from long-lived PC which is already evident by the fact that their 
major effector function lies in their reactivation and that they can be found circulating 
in blood without immunization. Specifically, in humans mBC constitute up to 40% of 
peripheral blood total B cells (90, 91). With regard to their tissue localization, based 
on certain observations, eligible candidate lymphoid tissues, that may provide niche 
conditions and soluble survival factors for mBC, are the BM, mucosal tissues, tonsil 
and the spleen.  
The BM already provides a unique survival niche for long-lived PC but also for reac-
tive memory T cells (92-94) and thus it is only logic to assume that it also may pro-
vide a niche to mBC. However, data on mBC in the BM are scarce. Solely, the 
presence of mature IgMpos B cells with mutated BCR gene rearrangements has been 
described (95, 96) but more detailed data on their proportion and characteristics are 
unavailable.  
In gut-associated lymphatic tissues (GALT) CD27pos B cells were found under the 
dome epithelium of Peyer’s patches (97) and in the inner wall of the subcapsular si-
nus of mesenteric lymph nodes (98). On B cells, moderate CD27 expression (i.e. 
CD27pos) has been proven useful to identify quiescent B cells that carry somatically 
mutated Ig gene rearrangements (91, 99), which is a hallmark of antigen-experienced 
B cells as well as CD27pos B cells resemble mBC in functional terms (reviewed in 
(100)). However, further studies of the CD27pos GALT B cells are also not available. 
With regard to the tonsil, the presence and functionality of reactive mBC have been 
described (71, 80, 101-103). Further their location has been determined to be mainly 
the mucosal crypt epithelium. But again, more detailed studies of the tonsillar mBC 
pool are lacking. 
Finally, the spleen has been considered as a major reservoir for mBC and thus may 
also provide a niche to them as supported by the following observations. Firstly, 
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CD27pos mBC are present in the spleen (99), usually organized around B cell follicles 
(104-107). Secondly, splenectomy greatly diminishes peripheral mBC numbers of 
both pre-switch mBC and post-switch mBC (108-110). Moreover, mBC generated 
during TD responses (vaccinia virus) were shown to persist in the spleen even 30 
years after the last antigen exposure (70). Interestingly, that study also identified vac-
cinia virus-specific mBC circulating in peripheral blood, albeit at smaller numbers. 
 
The fact that mBC can be found in peripheral blood at the same time as they are 
spread out in different lymphoid tissues and organs suggests their recirculation. Yet, 
it remains to be determined, whether a certain proportion of them is sessile once they 
have reached their favored location or niche, waiting to become reactivated, as would 
be suggested by experiments conducted by Gowans and Uhr (111). 
To gain insight into these aspects, a comprehensive mapping, including enumeration 
and phenotyping of mBC within different lymphoid organs would be a starting point 
and has so far not been performed, neither in mice nor in humans. Yet, gaining more 
knowledge about mBC lifestyle is of obvious interest not only for enhancing our un-
derstanding of immune memory but therapeutically more important also for autoim-
mune conditions and other long lasting immunological disorders, as when 
autoantigen-specific or allergen-specific B cells establish a mBC pool their long-term 
survival and reactivation characteristics can become of dramatic pathogenic im-
portance. 
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3.3 Aims and objectives 
B cell memory is an essential component of immunologic memory. A thorough un-
derstanding of it will assist the development of new vaccination strategies but also to 
improve current therapeutic strategies of immunological disorders. The medical need 
became apparent by our recent limitations to provide efficient vaccinations to current 
pandemics (Ebola, HIV), due to failure of induction of protective antibody titers, or 
inducing remission of autoimmune diseases as the long-term efficacy of current ther-
apies is impeded by pathogenic immune memory maintenance and reactivation. 
Thus, we lack knowledge of the molecular and cellular mechanisms underlying pri-
mary B cell responses in humans during which memory is established. Furthermore, 
the life style and maintenance of human B cell memory remains also largely un-
known. 
 
Therefore, the current thesis investigated the initial induction of human antigen-
specific plasma- and memory B cells and also reactivation of the latter. The main aim 
was to enhance our understanding of the induction of antigen-specific Ig and princi-
ples of B cell selection and recruitment into the B cell memory pool. Further, memory 
B cells were enumerated and characterized in tissues likely providing a protected 
environment. Peripheral blood memory B cells were monitored during absence of the 
one or other organ in humans to better identify the role of potential survival organs or 
niches. 
 
Therefore, firstly, primary and secondary KLH immunization was employed and the 
induced KLH-specific serum antibody levels as well as plasma- and memory B cells 
quantified. The results should provide first insights into the serologic and B cellular 
response kinetics and characteristics permitting conclusions on the principles of 
these responses. 
 
Secondly, the quality of the resulting B cell responses were studied by molecular 
analyses of Ig heavy chain gene rearrangements of circulating KLH-specific B cell 
subsets. In order to do so, KLH-specific sequences were analyzed for their Ig gene 
family usage, repertoire composition, frequency of somatic mutations and clonal ex-
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pansion. The results should permit insights into repertoire recruitment characteristics 
and the process of affinity maturation during primary and secondary immunization as 
well as they should allow conclusions on the B cells’ origin. 
 
Thirdly, antigen-specific Ig repertoire comparisons between the primary and second-
ary response as well as the steady state KLH-specific memory B cell repertoire were 
performed. The results should reveal relationships between the KLHspec B cell pools 
and thus allow conclusions on memory formation, characteristics of reactivation and 
Ig diversification. 
 
Fourthly, the distribution and organ-specific phenotype of the overall human memory 
B cells and antigen-specific memory B cells in spleen, tonsil and bone marrow com-
pared to peripheral blood were studied. Finally, the impact of the absence of spleen 
or tonsil on memory B cell maintenance was investigated. The results should grant 
insight into compartmentalization of reactive B cell memory and its organization. 
 
The overall aim of the study was to gain deeper insights into the principles of memory 
induction, maintenance and reactivation by using a defined vaccination model in hu-
mans. The thesis studies led to innovative insights that allow to roll out new concepts 
of memory B cells and will fertilize vaccination and immunotherapeutic approaches.  
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4. Materials and Methods 
4.1 Materials 
Table 4-1: Universal materials 
Reagent / Material Manufacturer 
Microcentrifugation / Safe-Lock Tubes  
1,5 mL / 2,0 mL 
Eppendorf AG, Hamburg, Germany 
Serological Pipettes (10 mL, 25 mL, 50 mL) Becton Dickinson (BD) Falcon, Heidelberg, Germany 
EDTA Vacutainer and serum Vacutainer tubes BD Biosciences, San Jose, CA, USA 
50 mL Conical Centrifuge Tube Corning Incorporated | Life Sciences, Acton, MA, USA  
15 mL Conical Centrifuge Tube Corning Incorporated | Life Sciences 
Phosphate buffered saline (PBS)  
w/o Ca2+ w/o Mg2+ low endotoxin 
Biochrom AG, Berlin, Germany 
Albumin, Bovine Fraction V (BSA) Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
Ultra Pure Water (H2O) Biochrom AG 
DAPI (4,6 diamidino-2-phenylindole; 220 nM) Molecular Probes, Eugene, OR, USA 
Table 4-2: Isolation of mononuclear cells from blood and tissue 
Reagent Manufacturer 
Ficoll–Paque Plus GE Healthcare Bio-science AB, Uppsala, Sweden 
70 µm cell strainer BD Biosciences, San Jose 
Quiagen Buffer EL Quiagen GmbH, Hilden, Germany 
Ultra PureTM 0.5 M EDTA (Ethylenediaminetet-
raacetic acid), pH 8.0 
Life Technologies, Carlsbad, CA, USA 
 
Table 4-3: Staining materials for flow cytometry and FACS 
Reagent Manufacturer 
BD Cytofix Fixation Buffer  BD Biosciences, San Jose 
BD Phosflow Perm Buffer III BD Biosciences, San Jose 
5 mL Polystyrene Round Bottom Tube Falcon, Corning Incorporated, NY, USA 
BD TrucountTM tubes BD Biosciences, San Jose 
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Table 4-4: Antigens 
Reagent Manufacturer 
Tetanus toxoid (TT) Lot 317470 Novartis Deutschland GmbH, Nürnberg, Germany 
Keyhole Limpet Hemocyanin (KLH) Biosyn, Fellbach, Germany 
 
Table 4-5: Conjugated antigens for flow cytometry and FACS 
Antigen Fluorochromelabel/ 
conjugated to 
Conjugated at 
TT Digoxigenin (Dig) DRFZ, Berlin, Germany 
TT Cy5 DRFZ, Berlin 
KLH Dig DRFZ, Berlin 
KLH Cy5 DRFZ, Berlin 
 
Table 4-6: Antibodies for flow cytometry and FACS 
Specificity of antibody Clone Fluorochromelabel/ 
conjugated to 
Manufacturer 
CD3 SK7 Allophycocyanin-H7 
(APC-H7) 
BD Biosciences, San Jose 
CD3 UCHT1 Pacific Blue (PacB) BD Biosciences, San Jose 
CD14 MOP9 APC-H7 BD Biosciences, San Jose 
CD14 M5E2 PacB BD Biosciences, San Jose 
CD19 SJ25C1 Phycoerythrin-Cyanine7 
(PE-Cy7) 
BD Biosciences, San Jose 
CD19 SJ25C1 APC-H7 BD Biosciences, San Jose 
CD20 L27 Peridinin-chlorophyll-
protein complex (PerCp) 
BD PharmingenTM, Heidelberg, 
Germany 
CD20 HI47 Pacific Orange (PacO) Invitrogen Corporation, Frederick, 
MD, USA 
CD27 2E4 Cyanine5 (Cy5) Kind gift from René van Lier, Ac-
ademic Medical Centre, University 
of Amsterdam, The Netherlands 
IgA M24A Fluorescein isothiocya-
nate (FITC) 
Chemicon, Temecula, CA, USA 
IgD IA6-2 PE BD Biosciences, San Jose 
IgM G20-127 PerCpCy5.5 BD Biosciences, San Jose 
IgG G18-145 PE-Cy7 BD Biosciences, San Jose 
CD24 ML5 FITC BD Biosciences, San Jose 
CD21 B-Ly4 PE-Cy7 BD Biosciences, San Jose 
CD31 WM59 PE BD Biosciences, San Jose 
CD38 HIT-2 PerCpCy5.5 BD Biosciences, San Jose 
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Specificity of antibody Clone Fluorochromelabel/ 
conjugated to 
Manufacturer 
CD45 2D1 PerCp BD Biosciences, San Jose 
CD54 HA58 PE Biolegend, San Diego, CA, USA 
CD62L Dreg-56 PE-Cy7 ebioscience, San Diego, CA, USA 
CD69 FN50 APC Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany 
CD95 DX2 PerCpCy5.5 BD Biosciences, San Jose 
β7 integrin FIB504 PE BD Biosciences, San Jose 
CXCR5 RF8B2 Alexa488 BD Biosciences, San Jose 
CXCR4 12G5 PE BD Biosciences, San Jose 
ICOSL HIL131 PE kind gift from Andreas Hutloff 
HLADR L243 FITC Kind gift from DRFZ 
Ki67 MIB-1 FITC Dako Denmark A/S, Glostrup, 
Denmark 
Dig, Fab fragments polyclonal FITC Roche Diagnostics GmbH, Mann-
heim, Germany 
 
Table 4-7: ELISpot 
Reagent Manufacturer 
MultiScreen flat-bottom 96-well plate 
(MSIPN4450) 
Merck Millipore, Ireland 
Ethanol 70% Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
1640 RPMI medium Gibco, NY, USA 
Fetal calf serum (FCS) Gibco, NY, USA 
Penicillin-Streptomycin Gibco, NY, USA 
Tween-20 Sigma-Aldrich, St. Louis 
Biotinylated anti-IgA antibody (mix of anti-IgA1 
and anti-IgA2, clone G20-359) 
BD Biosciences, San Jose 
Biotinylated anti-IgM antibody (polyclonal) Sigma-Aldrich, St. Louis 
Biotinylated anti-IgG antibody (polyclonal) Sigma-Aldrich, St. Louis 
ExtrAvidin-Peroxidase Sigma-Aldrich, St. Louis 
3-amino-9-ethylcarbazole Sigma-Aldrich, St. Louis 
N,N-dimethylformamide Sigma-Aldrich, St. Louis 
Sodium actetate Sigma-Aldrich, St. Louis 
Acetic acid buffer Sigma-Aldrich, St. Louis 
H2O2 Sigma-Aldrich, St. Louis 
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Table 4-8: RT-PCR and cDNA synthesis 
Reagent Manufacturer 
Titan One Tube RT-PCR System 
- 5x R- PCR-Buffer  
- Enzyme mix (reverse transcriptase, AMV) 
- DTT (100 mM)  
Roche Diagnostics GmbH 
Deoxynucleotide (dNTP) Mix (each 10 mM) Sigma-Aldrich Chemie GmbH, Steinheim 
Primer p(dT)15 (800 ng/mL) Roche Diagnostics GmbH 
RNasin Plus Rnase inhibitor® (40 U/µL) Promega,Madison, WI, USA 
Spermidin (50 nM) Sarka Ruzickova, Prague,Czech Republic  
Triton-X-100  Sigma-Aldrich Chemie GmbH, Steinheim 
 
Table 4-9: Nested PCR 
Reagent Manufacturer 
AmpliTaq DNA Polymerase kit (N808-0153)  
- AmpliTaq® DNA Polymerase 
- GeneAmp® 10x PCR Buffer II 
- GeneAmp® MgCl2-Solution (25 mM) 
Applied Biosystems, Foster City, CA, USA 
Primer for external PCR (100 pmol/µL) Metabion, Martinsried, Germany 
 VH1 LC   5’ CC ATG GAC TGG ACC TGG A 3’ 
 VH2 LC  5’ ATG GAC ACA CTT TGC T(AC)C AC 3’ 
 VH3 LC   5’ CC ATG GAG TTT GGG CTG AGC 3’  (112) 
             VH4 LC   5’ ATG AAA CAC CTG TGG TTC TT 3’       
 VH5 LC  5’ ATG GGG TCA ACC GCC ATC CT 3’ 
 VH6 LC   5’ ATG TCT GTC TCC TTC CTC AT 3’ 
 IgA : IgVH-cα         5’ GGA AGA AGC CCT GGA CCA GGC 3’ (113) 
 IgG: Ecγ∗  5’ AC GCC GCT GGT CAG GGC GC 3’   
 IgM: Ecµ  5’ TCA GGA CTG ATG GGA AGC CC 3’   
Primer for internal PCR (100 pmol/µL) Metabion, Martinsried 
 VH1 FM  5’ CAG GTG CAG CTG GTG CAG TCT GG 3’ 
 VH2 FM  5’ CAG GTC ACC TTG AAG GAG TCT GG 3’ 
 VH3 FM  5’ GAG GTG CAG CTG GTG GAG TCT GG3’      (114) 
 VH4 FM  5’ CAG GTG CAG CTG CAG GAG TCG GG3’ 
 VH5 FM  5’ GAG GTG CAG CTG GTG CAG TCT GG3’ 
 VH6 FM  5’ CAG GTA CAG CTG CAG CAG TCA GG3’ 
 IgA: IgAex2  5’ ACC AGG CAG GCG ATG ACC AC 3’        
 IgG: IgGex*  5’ AAG TAG TCC TTG ACC AGG CAG C3’     (115), modified 
 IgM: IgMin,neu             5’ AGG AGA CGA GGG GGA AAA GGG TTG 3’     (115), modified 
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Table 4-10: PCR product purification 
Reagent Manufacturer 
10x Tris-borate-EDTA (TBE) Carl Roth GmbH & Co 
Biozym LE Agarose Biozym Scientific GmbH, Oldendorf, Germany 
mi-100bp+ DNA Marker (0.1 µg/µL) Metabion, Martinsried 
GelRedTM Nucleic Acid Gel Stain Biotium, Inc., Hayward, CA, USA 
tRoti®-Load-DNA short-run  
(supplemented with 1 mL glycerol, 8 mL H2O and 
1:5000 GelRedTM) 
Carl Roth GmbH & Co 
QIAquick®Gel Extraction Kit (250) 
- QG Buffer 
- PE Buffer 
- EB Buffer 
- QIAquick spin column 
Qiagen, Hilden, Germany 
Isopropanol Carl Roth GmbH & Co 
Ethanol 96% Carl Roth GmbH & Co 
 
Table 4-11: Other reagents and materials 
Reagent/ Material Manufacturer 
Abgene®PCR Plates Thermo-Fast®96, Low Pro-
file 
Thermo Fisher Scientific, Bonn, Germany 
PCR-adhesive foil VWR International GmbH, Dresden, Germany 
Domed cap strips Thermo Fisher Scientific 
Glycerol Merck, Darmstadt, Germany 
96 well microtiterplates, V-form VWR International GmbH 
 
Table 4-12: Devices 
Device Manufacturer 
BD FACSAria flow cytometer special order system BD, Heidelberg, Germany 
BD FACSCanto II flow cytometer BD, Heidelberg 
Centrifuge 5415C / 5415D Eppendorf AG 
DS34 Direct Screen Instant Camera with  
GH26 Electrophoresis Hood 
Polaroid, Dreieich-Sprendlingen, Germany 
Electrophoresis chamber C.B.S. Scientific Co, Del Mar, CA, USA 
Labofuge 400e Heraeus Instruments, Hanau, Germany 
MaxiCycler PTC-100  Biozym Diagnostic GmbH 
MultiCycler PTC-200 Biozym Diagnostic GmbH 
Transilluminator 312nm Herolab GmbH, Wiesloch, Germany 
ELISpot Reader and Immunospot Software CTL, Aalen, Deutschland 
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4.2 Methods 
4.2.1 KLH immunization and study participants 
Five healthy volunteers (HD; 1 male, 4 female, age range 27 to 54 years) were en-
rolled in the KLH immunization study. Donors received a parenteral immunization of 
either 0.6 mg KLH subcutaneously (s.c.; HD1) or 0.1 mg KLH s.c. (HD2 and HD3) or 
0.5 mg KLH s.c. and 0.5 mg KLH intradermally (i.d.; HD4 and HD5) in the deltoid re-
gion. A booster dosis was injected 7 (HD4 and HD5) or 10 days (HD1-HD3) after-
wards with 1 mg s.c. or 0.1 mg s.c., respectively. Donors HD1, HD2 and HD3 
received a secondary immunization 18 months (HD1; 0.1 mg s.c.) or 6 months (HD2 
and HD3; 0.01 mg s.c.) after the primary immunization cycle. 10 mL serum and 10-20 
mL EDTA venous blood (BD Vacutainer) was obtained before and at several time 
points after immunization as depicted in the figures (see section 5.1). The study was 
approved by the local ethics committee and informed consent was obtained by the 
individuals participating in this study. 
4.2.2 Tissue distribution of B cells and mBC study participants 
For the comparative analysis of mBC between blood and lymphoid organs, 10-50 mL 
venous peripheral blood (EDTA, BD Vacutainer) from 40 HD (23 female, 17 male, 
age range 23-63 years), from 10 tonsillectomized HD (TX, 3 female, 7 male, 26-65 
years) and 6 splenectomized donors (S1-S6, 4 female, 2 male, 36-73 years) was col-
lected. S1, S2, S4 and S5 were splenectomized because of immune thrombocytope-
nia (ITP) and S3 and S6 because of non-immunological diseases. To confirm the 
absence of splenic function, blood smears were examined for Howell-Jolly-bodies 
(116). 
Altogether 23 tonsils were obtained from patients (12 female, 3 male, 8 unknown, 11-
51 years) undergoing tonsillectomy due to tonsillitis. A total of 10 spleen samples 
were obtained from patients (6 female, 4 male, 16-79 years) of that four underwent 
splenectomy because of ITP and the other six for non-immunological reasons. Thirty-
four BM samples were obtained from patients (23 female, 10 male, 1 unknown, 35-82 
years) undergoing hip joint replacement surgery. Written informed consent was ob-
tained in all cases in accordance with the local ethics’ committee of the Charité Uni-
versitätsmedizin Berlin. 
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4.2.3 Mononuclear cell- and serum isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from fresh EDTA blood by 
density gradient centrifugation using Ficoll-Paque Plus (according to the principle 
described by Bøyum (117)). Therefore, blood was 1:1 (V/V) mixed with PBS and 30 
mL of this mixture layered on to 15 mL Ficoll-Paque Plus solution in a 50 mL conical 
centrifugation tube and centrifuged for 20 min at 400xg (brakes off, all at RT). Due to 
different cell densities and with respect to the properties of the Ficoll-Paque Plus so-
lution, differential migration during centrifugation resulted in the formation of layers 
containing the different cell types. In short, erythrocytes and granulocytes form a lay-
er at the bottom of the tube, followed by a layer of Ficoll-Paque Plus solution on 
which a ring like interface contains the lymphocytes, monocytes and platelets, fol-
lowed by the top layer, i.e. the plasma. The lymphocyte-containing ring was recov-
ered from the interface and transferred into a new 50 mL conical centrifugation tube 
and washed twice with 4 °C cold PBS/0.2% BSA at 200xg at 4 °C for 10 min. The 
obtained PBMC were then filtered through a 70 µm cell strainer.  
Spleen and tonsil specimens were minced, respectively, and vortexed in PBS/BSA. 
The resulting cell suspensions were filtered (70 µm cell strainer) and mononuclear 
cells (MNC) isolated as performed for PBMC. BM samples were either treated as de-
scribed for spleen and tonsil specimens but using PBS/BSA/5mM EDTA or after filtra-
tion residual erythrocytes were lysed using Quiagen Buffer EL. Therefore, the filtered 
BM cell suspension was mixed 1:4 (V:V) with the Quiagen Buffer EL in a 50 mL coni-
cal centrifugation tube and incubated for 15 min on ice. This suspension was centri-
fuged afterwards at 180xg at 4 °C for 10 min, and washed twice with cold 
PBS/BSA/EDTA and finally filtered (70 µm cell strainer). 
For serum collection, serum blood was centrifuged at 1500xg for 10 min at RT. Serum 
was stored at -21 °C until use.  
4.2.4 Flow cytometric analysis 
Flow cytometry is a laser-based widely used biophysical technique for the rapid anal-
ysis of multiple characteristics of single cells. In short, cells from a suspension are 
hydrodynamically focussed in a stream of fluid and passed by several laser beams 
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and an electronic detection apparatus recording how the cell or particles scatter inci-
dent laser light and emit fluorescence. Hence, it measures optical and fluorescence 
characteristics of these single cells based on their physical properties (e.g. size, 
granularity) and cellular components or reaction products labeled with fluorescent 
dyes, either directly (e.g. DNA or RNA intercalating reagents) or indirectly by fluoro-
chrome-labeled antigens or antibodies targeting specific proteins. The underlying 
principles and applications of flow cytometry and also of fluorescence activated cell 
sorting (FACS), which provides a method for isolating individual cells from the heter-
ogeneous cell suspension, has been expertly summarized in detail elsewhere (118).  
4.2.4.1 Surface staining procedures 
To characterize and isolate KLH-specific (KLHspec) B cells, PBMC were stained with a 
basic mix of antibodies against CD3, CD14, CD19, CD20, CD27 (Table 4-6) and KLH 
which was either labeled to Cy5 or to Dig. For the latter combination a second stain-
ing step after washing with anti–Dig-FITC was required. KLHspec B cells were identi-
fied by their binding to the labeled KLH. The specificity of the antigen staining was 
confirmed each time by blocking with unconjugated KLH (50x-200x excess) which 
was added 5 min prior to the regular staining. TTspec B cells were identified by their 
binding to Cy5-labeled TT (TT-Cy5) and the specificity of this staining was also con-
firmed each time by blocking using unconjugated TT, as described for KLH. 
For the stainings designed to characterize lymphoid organ and blood B cells and 
mBC, a basic staining mix containing CD3, CD14, CD19, CD20 and CD27 was used 
in different combinations of antibodies (Table 4-6) were added. Additionally, for each 
of the antibodies, the respective isotype control was stained in a fluorescence minus 
one control manner. 
For the principle cell surface staining procedure, a volume of 50 µL containing ~1x106 
PBMC/MNC in PBS/BSA was used. To this, the respective antibodies or antigens 
were added. Stainings were performed in the dark at 4°C for 15 min, followed by 
washing in 2 mL PBS/BSA at 200xg for 5 min. DAPI was added immediately before 
flow cytometric analysis. PBMC/MNC were analyzed using a BD FACSCanto II flow 
cytometer. 
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4.2.4.2 Intracelluar staining for Ki67 
Intracellular Ki-67 staining was performed upon surface staining with the basic B cell 
staining mix, as described above, only that 100 µL containing ~2x106 PBMC/MNC 
were used. PBMC/MNC were then washed three times with 3 mL PBS followed by 
their thorough resuspension in the reflux after discarding the supernatant. For fixa-
tion, 250 µL BD Cytofix Fixation buffer was added while vortexing and the cells incu-
bated for 10 min at 37 °C followed by washing with 2 mL PBS at 400xg for 5 min. 
Resuspended cells were again washed (400xg for 5 min) with 2 mL PBS/1% BSA 
followed by their thorough resuspension in the reflux after discarding the supernatant. 
For permeabilization, 500 µL BD Phosflow Perm Buffer III was added slowly while 
gently vortexing and cells were incubated for 30 min on ice in the dark. Permeabilized 
cells were washed twice with 3 mL PBS/BSA at 400xg for 5 min. Resuspended cells 
were stained with the Ki-67-FITC antibody at RT for 30 min in the dark and washed 
afterwards in PBS/BSA. 
4.2.5 Enzyme-linked immunospot assay (ELISpot) for detection of indi-
vidual PB secreting KLH-specific antibodies 
ELISpot is a method which enables the monitoring of individual cells within a cell 
population or generally PBMC by detection of their secreted products, as a modifica-
tion of a traditional sandwich ELISA immunoassay. In brief, a suspension of cells is 
seeded ideally in an adequate dilution to form a monolayer on a polyvinylidene fluo-
ride-membrane microtiter plate which has been coated either with e.g. an antigen or 
a capture antibody followed by incubation and subsequent detection steps. Each spot 
that develops represents a single cell and thus provides qualitative and quantitative 
information. In this study it is used to detect antigen-specific antibody secreting cells 
from peripheral blood, i.e. PB, from KLH immunized donors. The technique’s principle 
is expertly explained in the original work by Czerkinsky et al. (119). 
To test for the KLH stainings’ general effectiveness to extract KLHspec B cells, KLH-
binding versus non-binding antibody-secreting cells, i.e. PB, gates as 
CD3negCD14negCD19posCD20low/negCD27highKLHpos and KLHneg cells, respectively, as 
well as bulk CD3negCD14negCD19posCD20low/negCD27high cells were isolated by FACS 
and subsequently seeded on a KLH-specific ELISpot. Therefore, prior to cell seeding 
a MultiScreen flat-bottom 96-well plate was prepared by pre-wetting with 35% ethanol 
for 1 min, followed by washing with PBS and incubation with 50 µL of 0.04 mg/mL 
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KLH at 37 °C for 1 hour. As controls, wells were incubated with undiluted human se-
rum and as well as with PBS/3% BSA. Afterwards, the plate was washed with PBS 
and the membrane blocked with PBS/3% BSA at 37 °C for 1 hour followed by wash-
ing with PBS/BSA. The by FACS isolated PB populations were seeded onto that 
plate and incubated overnight in 1640 RPMI medium, supplemented with 10% FCS 
and 1% penicillin/streptomycin in a humid atmosphere (plate covered) at 37 °C/5% 
CO2. On the following morning the cells were removed by thorough washing six times 
with PBS/1%BSA/0.05% Tween-20. For detection of secreted KLH-specific antibod-
ies, a mix of biotinylated anti-IgA, anti-IgM and anti-IgG was added in a 1:200 PBS 
dilution. The plate was then again incubated at RT for 1 hour followed by vigorous 
washing six times with PBS. For detection of the biotinylated antibodies, the plate 
was incubated at RT for 30 min with ExtrAvidin-Peroxidase diluted 1:3000 in PBS. 
Afterwards the plate was again washed with PBS. Subsequently, 5 min incubation 
with 3-amino-9-ethylcarbazole dissolved in N,N-dimethylformamide, diluted in a 0.2 M 
sodium actetate/0.2 M acetic acid buffer supplemented with H2O2, was used to de-
velop bound antibody and was followed by thorough washing under the tap (deion-
ized water). The plate was analyzed by an ELISpot reader after drying overnight. 
4.2.6 ELISA for detection of anti-KLH serum antibodies 
ELISA for quantification of serum anti-KLH IgM, IgA and IgG antibodies, respectively, 
were performed by the laboratory of Dr. J.F.M. Jacobs (Radboud University Medical 
Centre, Nijmegen, The Netherlands) according to their published protocol by 
Aarntzen et al. (120). In short, KLH antibodies were purified from each serum sample 
by washing the serum over a KLH-coated column (Alpha Diagnostics International, 
San Antonio, Texas, USA) followed by washing and elution of the antibodies. Differ-
ent concentrations of each respective eluate were added on 96-well plates coated 
with 5 µg/mL KLH (Biosyn) at RT for 1 hour. After washing, specific antibodies 
against human IgM, IgG and IgA, respectively, labeled with horseradish peroxidase 
(all Invitrogen, San Diego, CA, USA) were added and incubated at RT for 1 hour. 
Upon subsequent washing, peroxidase activity was revealed using 3,3′,5,5′-
Tetramethylbenzidine (Sigma-Aldrich) as substrate. The reaction was stopped with 
sulphuric acid and absorbance was determined at 450 nm. A detection limit of the 
anti-KLH ELISA was determined by the laboratory as described (120). 
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4.2.7 Single-cell PCR for IgH sequence analysis 
Single-cell analyses generally provide powerful tools to gather information not only on 
an entire cell population but on a cell individual level, which yet can be expanded to a 
population level again, depending on the quantity of analyzed events, as can be very 
easily comprehended from FACS analyses.  
Single-cell DNA or RNA analysis is an informative tool in the analysis of genetic ma-
terial providing information on e.g. cell clonality, detection of genetic disorders from 
embryos, analysis of transgenic animals and/or the absolute abundance of e.g. 
mRNAs or microRNAs and their up- or downregulation in a single cell compared to 
neighboring cells. In this regard and with respect to the current study, polymerase 
chain reaction (PCR) is a particularly useful tool when the amount of genetic material 
is very limited because single copies of (expressed) genes can be detected. PCR 
relies on a principle where a DNA polymerase synthesizes a new strand of DNA 
complementary to the offered template strand during cycles of repeated heating and 
cooling required for the different PCR steps, i.e. DNA denaturation, primer annealing 
and template elongation. At the end, the specific target sequence will be accumulat-
ed in millions of copies, so termed amplicons, which can be made visible on e.g. an 
agarose gel.  
In the here conducted study, expressed IgH genes were reverse transcribed by re-
verse transcription- (RT-) PCR and the target sequences subsequently amplified by a 
nested PCR protocol, i.e. a two-step amplification PCR. The first PCR step is called 
external PCR with a set of external primers of which the product is used as template 
for the second PCR step termed internal PCR using internal primers, which are in-
dented in the product from the external PCR. The correct PCR product (according to 
size) is isolated from an agarose gel and sequenced. The process is illustrated in 
Figure 4-1.  
Therefore, PBMC were stained as described under section 4.2.4.1 and individual 
KLHspec PB or mBC sorted into a 96-well plate, using a BD FACSAria flow cytometer. 
DAPI was added immediately before cell sorting to exclude dead cells. Each well al-
ready contained 30 µL of a mix for cell lysis and RNA stabilization, consisting of 8.3 
mM DTT, 0.5 µg BSA, 1.7% TritonX-100, 0.8 nM Spermidin, 0.4 ng p(dT)15 Primer 
and 20 U RNasin Plus RNase inhibitor.  
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Figure 4-1 Schematic overview of KLHspec B cell isolation by FACS and the single-cell PCR ap-
proach for amplification of the KLHspec IgH chain.  
The amplification of IgH sequences from KLHspec PB and mBC, respectively, was achieved by RT PCR 
from mRNA of single isolated cells, followed by a multiplex nested PCR. The external forward primers 
were located in the leader sequence of the mRNA. Six VH family specific forward primers were used in 
the external and internal PCR, respectively, amplifying segments from all VH families, including VH7. 
For the constant region (reverse primers), for each major isotype (IgA, IgG or IgM) an individual primer 
was used. 
 
Afterwards, 20 µL of a second mix was added containing the Titan One Tube kit’s 
RT-PCR buffer (10 µL) and 1 µL AMV reverse transcriptase supplemented with 0.5 
mM dNTPs. Exemplarily for one well, individual component volumes for mix 1 and 
mix 2 are shown in Table 4-13. Complementary DNA (cDNA) was generated at 50 °C 
for 60 min.  
Table 4-13 Example mix RT PCR 
Mix 1 Volume per well Mix 2 Volume per well 
H2O 20.95 µL H2O 8 µL 
0.1 M DTT 2.5 µL 5x RT-PCR-Buffer 10 µL 
40 U/µL RNasin 0.5 µL dNTP Mix (10 mM ea) 1 µL 
50 nM Spermidin 0.5 µL Enzyme mix (AMV) 1 µL 
10 µg/mL BSA 0.05 µL   
800 ng/mL p(dT)15 Primer 0.5 µL   
10 % Triton-X-100 5 µL   
 
Amplification of rearranged VHDJHCγ/α/µ sequences from the bulk of generated 
cDNA was facilitated by nested PCR using 5 µL of the cDNA, followed by product 
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purification and sequencing. For both, the external and internal PCR, the reaction mix 
consisted of the AmpliTaq DNA Polymerase kit components prepared according to 
the manufacturer’s instruction, supplemented with 0.2 mM dNTP and 0.07 µM of 
each of the external and internal primers (Table 4-9), respectively. 5 µL of the exter-
nal PCR products were used as template for the internal PCR. Table 4-14 shows an 
example mix for external and internal PCR, containing all VH forward primers for full 
repertoire analysis and reverse primers for IgM, IgA and IgG transcript amplification. 
The external PCR cycle program consisted of 7 min at 95 °C, 1 min at 50 °C, 90 sec 
at 72 °C, followed by 50 cycles of 1 min at 94 °C, 30 sec at 50 °C, 90 sec at 72 °C 
and to finish 1 min at 94 °C, 30 sec at 50 °C, 10 min 72 °C. For the internal PCR, the 
same cycle program was used with the exception of the primer annealing tempera-
ture which was 58 °C. 
Table 4-14 External and internal PCR reaction mix example with all forward and reverse primers 
External PCR mix Volume per well Internal PCR mix Volume per well 
H2O 56.4 µL H2O 56.4 µL 
10x PCR Buffer II 8 µL 10x PCR Buffer II 8 µL 
MgCl2 Solution 8 µL MgCl2 Solution 8 µL 
dNTP Mix (10 mM ea) 1.6 µL dNTP Mix (10 mM ea) 1.6 µL 
Amplitag DNA Polymerase 0.5 µL Amplitag DNA Polymerase 0.5 µL 
VH1 LC 0.056 µL VH1 FM 0.056 µL 
VH2 LC 0.056 µL VH2 FM 0.056 µL 
VH3 LC 0.056 µL VH3 FM 0.056 µL 
VH4 LC 0.056 µL VH4 FM 0.056 µL 
VH5 LC 0.056 µL VH5 FM 0.056 µL 
VH6 LC 0.056 µL VH6 FM 0.056 µL 
IgA : IgVH-cα 0.056 µL IgA: IgAex2 0.056 µL 
IgG: Ecγ∗ 0.056 µL IgG: IgGex* 0.056 µL 
IgM: Ecµ 0.056 µL IgM: IgMin,neu 0.056 µL 
 
25 µL to 50 µL of PCR products were mixed with 20 µL tRoti-Load loading buffer and 
were separated by agarose gel electrophoresis, on a 1.8% agarose gel dissolved in a 
0.5% TBE buffer. DNA fragments were visualized with GelRed by exposition to UV 
light, cut out and purified using QIAquick Gel Extraction kit according to the manufac-
turer’s instructions. In short, each gel slice (equalling a volume of ~200 µL) was incu-
bated with 600 µL QG buffer for 10 min at 50 °C until the gel slice dissolved 
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completely. Then, 200 µL isopropanol were added and the mix vortexed and placed 
on to a QIAquick spin column and centrifuged for 1 min at 10000xg. The flow-through 
was discarded and 500 µL QG buffer added, the tube centrifuged again and the flow-
through discarded. To wash, 750 µL PE buffer (supplemented with 96% ethanol) 
were added, let stand for 5 min and the column centrifuged again. The flow-through 
was discarded and the residual PE buffer-ethanol mix removed by another centrifu-
gation step. The QIAquick column was then placed into a new 1.5 mL microcentrifu-
gation tube and let stand open for 10 min so the residual ethanol could volatilize. To 
elute the DNA, 30 µL of EB buffer was added and the column centrifuged again at 
10000xg for 1 min. Products were sequenced at Eurofins MWG Operon (Martinsried, 
Germany). 
4.2.8 Data analysis 
4.2.8.1 Flow cytometry data 
Flow cytometry data were analyzed using FlowJo software 7.6.5 (TreeStar, Ashland, 
OR, USA) or BD FACSDiva 6.1.3. software. Absolute numbers of B cells, mBC or 
TTspec mBC were approximated by multiplying the described tissue-specific lympho-
cyte number (121), with the ratio of gated B cells, mBC or TTspec mBC, respectively, 
to gated total lymphocytes. 
4.2.8.2 IgH sequence analysis 
IgH sequences were analyzed using the Chromas 2.33 sequence viewer (Chromas 
Technelysim, Helensvale, Australia) and the joinsolver software (accessed between 
May 2012 and June 2014) using the Kabat database (122). Thereby, the joinsolver 
algorithm assigned VHDJH germline genes based on the highest homology. SHM 
were counted within VH genes from FWR1 to FWR3, which includes IgH chain CDR1 
(CDRH1) and CDRH2 and excludes the CDRH3 region. Isotype subclasses were 
determined by sequence comparison to the genomic sequence references from the 
ensemble human genome browser data base.  
Genomatix (123) was used for alignments and homology analyses of the sequences. 
As basis for construction of genealogic trees, firstly phylograms were created using 
phylogeny.fr (124). A search for common sequence motifs within CDRH3 regions 
was conducted using the MEME suite, ClustalW and Weblogo (125-128).  
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Mutation rates of primary KLHspec PB sequences were calculated with the formula 
Equation 1 Mutation rate. 
 
with the VH length given in base pairs (bp) of the respective corresponding VH region 
length and an assumed generation time of 8 hours, according to the estimated divi-
sion time of GC CB (129). Of note, this hypothetical natural mutation rate calculation 
was taken to its extremes by assuming that the division was maintained over the en-
tire course of the 14-18 days from time point zero, i.e. injection of the KLH.  
Since the number of isolated sequences was larger than the number of unique rear-
rangements (Figure 5-17) a statistical prediction of actual repertoire sizes could be 
made using an approach described by Behlke et al. (130). Accordingly, the probabil-
ity of observing exactly d distinct gene rearrangements among a total number of r 
examined sequences for a fixed number n of distinct gene rearrangements can be 
described as the likelihood (repertoire size) estimates with the equation 
Equation 2 Repertoire size. 
 
whereby S(r,d) are the Stirling’s numbers of the second kind and with the assumption 
that no significant skewing of the data set by nonrandom gene segment usage oc-
curred. For each day and donor, a maximum likelihood estimate (n for P(d)max) of the 
the clonal repertoire and a 95% one-sided confidence limit (n for P(d)<0.05) of the 
maximum likelihood estimates was calculated.  
4.2.8.3 Statistical analysis 
GraphPad Prism Version 5 for Windows (GraphPad Software, San Diego California, 
USA), Microsoft Excel 2010 (Santa Rosa, CA, USA) and R (131) were used for statis-
tical analyses. To determine significant differences between B cell populations re-
garding distributions of VH and JH gene usage, respectively, the χ2- goodness-of-fit 
statistic was calculated. Where appropriate to compare the distributions of two 
groups, the Mann-Whitney test was used. To compare paired values the Wilcoxon 
matched pairs test and paired t-test was performed, respectively. Which test was 
used for the respective data set is specified in the figure legends.  
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To calculate for statistical dependence between two variables the Spearman's rank 
correlation coefficient was calculated.  
Generally, an alpha of 0.05 or 0.01 was chosen as cutoff for statistical significance. 
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5. Results 
Immunological memory mediates our long-term protection from ubiquitous or recur-
ring pathogens. Yet its induction and maintenance are so far incompletely under-
stood, especially in humans. To address these aspects, this study investigated the 
induction, maintenance and reactivation of human antigen-specific B cell memory. 
Therefore, a comprehensive characterization of human primary- and secondary im-
mune responses was conducted. Secondly, a so far unique systemic quantification 
and characterization of mBC within different human lymphoid organs compared to 
those detectable in peripheral blood was performed.  
5.1 Direct comparison of a human KLHspec B cell response  
induced by primary versus secondary immunization 
To gain insights in to the underlying processes of PB and mBC generation as well as 
of reactivation of the latter we firstly utilized parenteral immunization with Keyhole 
Limpet Hemocyanin (KLH) in 5 naïve donors. KLH is a naturally occurring respiratory 
protein of the giant keyhole limpet Megathura crenulata living in shallow coastal wa-
ters in the sea (132, 133) and is usually not encountered by humans wherefore prior 
exposure or sensitizations of the immune system is unlikely. In the past, it has been 
utilized in studies addressing the phenomenon known as oral tolerance which result-
ed in useful insights how parenteral immune responses can or even cannot be ma-
nipulated by oral antigen feeding (134-136). Albeit soluble proteins are supposed to 
be poorly immunogenic when injected without adjuvants, KLH is immunogenic after 
all and elicits robust B- and T cell responses. Therefore, most recently it is used as a 
protein carrier to numerous poorly immunogenic cancer antigens, e.g. in melanoma 
(137), non-Hodgkin lymphoma (138) and follicular lymphoma (139). Hence, these 
applications underpin its functionality and principle safety for human studies.  
To determine antibody and B cell kinetics and examine the employed specific BCR 
repertoire in response to KLH administration the present study used direct staining of 
PBMC with fluorochrome-labeled KLH and FACS-isolated KLH-specific (KLHspec) B 
cells for molecular analyses.  
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5.1.1 Establishing a KLH-specific B cell staining 
Popular methods to determine the frequency of antigen-specific B cells include B cell 
ELISpot (140) and limiting dilution assay (141), which however both preclude a fur-
ther downstream isolation and characterization of the specific cells. To overcome this 
limitation, I established the direct staining of human KLHspec B cells using KLH cou-
pled to a fluorochrome or hapten, i.e. Cy5 or Dig, and flow cytometry allowing enu-
meration, further characterization and isolation of the specific cells. Figure 5-1 
illustrates the staining’s principle. 
 
Figure 5-1 Staining principle of antigen-specific B cells and flow cytometry.  
The green star indicates the fluorochrome or hapten that is covalently coupled to the immunizing anti-
gen, here KLH, followed by the product’s usage to stain PBMC. Stained PBMC are then analyzed on a 
flow cytometer. Only B cells (shown as blue cells) with an antigen-specific BCR should recognize the 
antigen and stain as positive cells while the rest should be unstained and therefore only exhibit a fluo-
rescence intensity equivalent to their autofluorescence and potential background, i.e. are detected as 
antigen-negative cells. 
 
To test for the staining’s specificity, three approaches were used. Firstly, competitive 
blocking controls with unlabeled antigen were performed. Secondly co-stainings with 
an irrelevant antigen, i.e. here tetanus toxoid (TT), were used to determine unspecific 
binding. An example of a KLHspec B cell staining, where KLH was stained in two 
channels simultaneously and the corresponding block, is shown in Figure 5-2 A. In 
Figure 5-2 B co-staining with the irrelevant antigen and its corresponding block is 
shown. The TT blocking control did not influence the binding of KLHspec mBC to KLH 
while the KLH blocking control did, as would be expected for specific B cells.  
As a result, in all following KLH experiments competitive blocking controls of the KLH 
staining were performed each time. 
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Figure 5-2 Specificity controls of the KLHspec B cell staining.  
A Shown are exemplarily mBC, gated as CD3negCD14negCD19posCD20posCD27pos cells, from HD1 7 
days upon secondary KLH immunization, which were stained with both simultaneously, KLH labeled to 
Cy5 and KLH labeled to Dig for the latter with secondary detection using a digoxigenin-specific FITC-
labeled F(ab)2 (aDigFITC). Left: unlabeled KLH (block) was added to the staining prior to adding the 
labeled KLH. Right: KLH staining without block. The gate marks the KLH-positively stained mBC, i.e. 
mBC carrying a KLH-specific BCR. B MBC were stained for KLH and tetanus toxoid (TT) simultane-
ously. Left: TT blocking control equivalently done as described under A for KLH. The gates show the 
areas where the specific B cells would be expected. Clockwise, starting from the top: TTspec mBC; 
double TTspec and KLHspec mBC, which would be considered as unspecific fluorescent labeling unless 
they would share a common epitope, and the right-corner rectangle gate marks the KLHspec mBC.  
 
Thirdly, to further also test for the staining’s efficacy to separate specific from non-
specific B cells, from blood obtained at day 16 after primary immunization for donors 
HD2 and HD3, KLH-binding PB (KLHpos) versus KLH-nonbinding PB (KLHneg) were 
isolated by FACS and seeded on an ELISpot plate specific for KLH (Figure 5-3, one 
representative example of two is shown).  
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Figure 5-3 Control of the KLHspec B cell staining’s efficacy to isolate specific cells.  
Sixteen days upon primary KLH immunization, KLH-binding (here: KLHpos) and KLH-non-binding 
(here: KLHneg) as well as a bulk PB population, respectively, were isolated from PBMC from HD2 by 
FACS and subsequently seeded overnight on a KLH-coated ELISpot plate (coated with 40 µg/mL 
KLH). Detection of secreted anti-KLH antibodies was carried out using a mix of anti-human IgM, IgG, 
and IgA-biotinylated antibodies, followed by secondary incubation with avidin-peroxidase and its sub-
strate 3-amino-9-ethylcarbazole. Black numbers in ELISpot-well-image indicate number of seeded PB. 
Orange numbers in ELISpot-well-image indicate number of spots. 
 
For both donors, we detected an enrichment of anti-KLH Ig secreting PB in the 
KLHpos fraction. In contrast, the PB bulk population contained very few anti-KLH Ig 
secreting PB and thus anti-KLH Ig producing PB were clearly de-enriched after sort-
ing in the KLHneg PB. This approves the staining efficacy and identification approach 
employed to extract KLHspec B cells from the bulk B cell population.  
5.1.2 Primary parenteral KLH immunization induced simultaneous in-
crease of anti-KLH IgM, IgG and IgA antibodies 
Initially, the pre-immunization status of the 5 volunteers hitherto unexposed to KLH 
was analyzed by testing for specific serum antibodies. Here, we found that pre-
immunization anti-KLH IgM, IgA and IgG antibody levels were either below or just 
above the lower limit of the assay’s detection level. In detail, where possible to de-
termine, specific titer levels ranged between 4.9 mg/L - 26 mg/L for IgG levels and 1 
mg/L - 13 mg/L for IgA. Subsequent parenteral immunization with soluble KLH did not 
cause a change of anti-KLH antibody levels until day 14. Interestingly, at this time 
point anti-KLH antibodies of all three major isotypes showed a rather simultaneous 
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increase, i.e. the appearance of IgM antibodies did not precede that of IgA or IgG 
antibodies. Further, anti-KLH IgA antibodies showed a similar increase as IgG anti-
bodies, i.e. 2- to 32- and 2- to 12-fold, respectively, yet specific IgA antibody levels 
remained below that of IgG antibodies at all times. Nevertheless, this clearly demon-
strates that IgA antibodies can be induced by a parenteral immunization. 
 
 
Figure 5-4 Kinetics of anti-KLH serum antibodies after primary parenteral KLH immunization.  
Donor HD1 received 0.6 mg KLH s.c., HD2 and HD3 received 0.1 mg KLH s.c., and HD4 and HD5 
received 1 mg KLH split into 0.5 mg s.c. and 0.5 mg i.d. in the upper arm. The KLH used for immuniza-
tion was in a soluble form without any adjuvant added. No value plotted means value was below de-
tection limit. 
5.1.3 The majority of induced KLHspec B cells belonged to the CD27pos 
and CD27high B cell populations 
Next, upon primary KLH immunization it was determined in which CD19pos B cell 
subpopulations KLHspec B cells appeared, as shown in Figure 5-5. As a result,     
KLHspec B cells were found within the CD27high B cell compartment, equaling the cir-
culating antibody-secreting PB/PC population (see Figure 5-3 and (142)), and the 
CD27pos B cell compartment, constituting the circulating mBC compartment in their 
majority (143, 144). Only in donor HD3, we found similar frequencies of KLHspec B 
cells in CD27pos and CD27neg B cell compartments, the latter comprising mainly naïve 
B cells, but also few mBC and transitional B cells.  
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Figure 5-5 Circulating KLHspec B cells are found in the CD27high and CD27pos B cell compart-
ments. 
A Dot plots of the appearance of KLHspec human CD3negCD14negCD19pos B cells exemplarily shown 
from donor HD1 on indicated days (d) after primary KLH immunization. For orientation, gates refer to 
KLHspecCD27high (upper gate) and KLHspecCD27pos (lower gate) cells, respectively. B Kinetics of the 
frequency of peripheral blood KLHspec PB detected by flow cytometry (left, gated as 
CD3negCD14negCD19posCD20neg/lowCD27highKLHpos cells), KLHspec mBC (middle, gated as 
CD3negCD14negCD19posCD20posCD27posKLHhigh cells) and KLHspec CD27neg B cells (right, gated as 
CD3negCD14negCD19posCD20posCD27negKLHhigh) on indicated time points after primary immunization 
expressed as percentages of the parent gate, respectively.  
5.1.4 Peripheral blood appearance of primary KLHspec PB                   
preceded that of KLHspec mBC 
Next, the kinetics of increase of blood KLHspec PB and mBC was determined. Gener-
ally, an increase of KLHspec PB was detectable in peripheral blood between days 7-24 
after primary immunization whereby variations between the individual donors were 
identified (Figure 5-5 B). Specifically, in HD1 KLHspec PB were detectable between 
days 7-21, but did not show an increase from day 7 (0.8%) to day 10 (0.4%). From 
day 10 to day 14, where also the peak increase was found (17.7%), KLHspec PB ex-
hibited a 44-fold increase. In HD2 and HD3, KLHspec PB were observed in peripheral 
blood on day 10 and thereafter until the last sampling time point, i.e. day 24. The 
peak response for both donors was detected on day 16 (4.6 % (HD2) and 6.1% 
(HD3)). In HD4 and HD5, few KLHspec PB were detectable on day 0 which however 
were not blockable. From day 7 to day 14 KLHspec PB were found 1.3- to 5-fold in-
creased to 17.3% (HD4) and 17.2% (HD5), respectively. These cells decreased 
thereafter but still were detectable until the end of the sampling period in a compara-
ble manner as found in the other donors.  
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In contrast to the appearance of primary KLHspec PB, KLHspec mBC exhibited slightly 
delayed and principle different kinetics of appearance. Firstly, KLH-binding mBC 
were detectable before immunization in 4 out of 5 donors, however, this KLH binding 
could be blocked poorly to 0% - 64% by pre-incubation with unlabeled KLH whereas 
at later time points, when KLHspec mBC re-appeared in blood (see below), the block 
was more efficient, i.e. a significant reduction of positively stained mBC of 57-100% 
was achieved (days 21/24; Figure 5-6).  
 
 
Figure 5-6 KLH-binding pre-primary immunization mBC were poorly blockable in contrast to 
post-immunization mBC. 
Frequency of KLHpos mBC with and without block before primary immunization (left) and 21 or 24 days 
after primary immunization (right). Paired t-tests were performed, with p≤0.05 considered to represent 
a significant change. 
 
Secondly, compared to day 0, KLHspec mBC were reduced or absent at day 7 and/or 
10 (HD2-HD5), i.e. the next time points measured, but found to be increased at day 
14 (HD4 and HD5) or a later time point (HD1-HD3; Figure 5-5 B middle graph). 
Thereby, KLHspec mBC showed their maximum increase between day 18 (HD1, HD4 
and HD5) and day 21 (HD2 and HD3), which was consistently later than the corre-
sponding KLHspec PB.  
5.1.5 Circulating KLHspec mBC and long-term anti-KLH serum antibodies 
were detectable after primary immunization 
Donors HD1-HD3 were re-analyzed 18 months (HD1) or 6 months (HD2 and HD3) 
after the primary, prior to secondary KLH immunization. Here, circulating KLHspec PB 
were absent in contrast to KLHspec mBC, which were readily detectable, ranging from 
0.084% to 1.76% from their parent-gated mBC population (Figure 5-7 A and B). Anti-
KLH IgG antibodies were reduced compared to the last sampling time point after pri-
mary immunization but still detectable at 20 mg/L - 40 mg/L corresponding to a 2.0- 
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to 6.0-fold increase to the pre-primary immunization levels (Figure 5-7 C). Anti-KLH 
IgA was also still detectable at levels 1.2- to 12-fold above the baseline levels before 
primary immunization. 
5.1.6 The secondary KLH serum response was dominated by IgG and 
exhibited an earlier onset compared to the primary one 
To determine whether the primary KLH immunization led to establishment of a func-
tional reactive memory, we next we examined the KLHspec B cell response to KLH 
booster immunization. Compared to primary immunization, secondary KLH immun-
ization induced different kinetics of appearance of peripheral blood KLHspec PB and 
mBC as well as a faster and heightened IgG dominated humoral response (Figure 
5-7).  
 
Figure 5-7 KLHspec PB, mBC and anti-KLH serum antibodies showed faster increase upon sec-
ondary immunization.  
A Dot plots of the appearance of KLHspec human CD3negCD14negCD19pos B cells exemplarily shown 
from donor HD1 on indicated days (d) after secondary KLH immunization. For orientation, gates refer 
to KLHspecCD27high (PB, upper gate) and KLHspecCD27pos (mBC, lower gate), respectively. B Appear-
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ance of KLHspec PB (left) and mBC (right) after secondary KLH immunization in peripheral blood. For 
secondary immunization which was performed 6 months (HD2 and HD3) or 18 months (HD1) after 
primary immunization, HD1 received 0.1 mg KLH s.c., and HD2 and HD3 both received 0.01 mg KLH 
s.c. each. B Serum titers of anti-KLH IgA, IgM and IgG antibodies after secondary immunization. No 
value plotted means value was below detection limit.  
 
In detail, circulating KLHspec PB and mBC were increased on day 7 in all three donors 
with subsequent contraction of KLHspec PB frequencies by day 14 (Figure 5-7 A and 
B). A further 2.4- to 3.2- fold increase of KLHspec mBC was detected in donors HD1 
and HD2, respectively. Anti-KLH IgG antibodies showed a strong 2.0- to 36-fold in-
crease, whereas IgA antibodies showed only a minor increment of 1.2- to 8-fold and 
IgM antibodies remained largely unchanged (Figure 5-7 C).  
These data suggest that primary KLH immunizations induced a reactive immunologi-
cal memory, i.e. a faster onset and higher magnitude response even to lower dosag-
es. The frequency increment levels of circulating KLHspec primary and secondary PB 
and mBC further revealed a slight but definite dose-dependence while this was not 
consistently observed on the serologic level.  
5.1.7 Parenterally-induced circulating KLHspec PB exhibited a high inci-
dence of IgA1 isotype usage in their IgH sequences 
Next, the composition of the by KLH engaged circulating KLHspec PB and mBC BCR 
repertoires was analyzed. This analysis was conducted to unravel IgH characteristics 
related to the underlying diversification and selection processes. Therefore, individual 
KLHspec PB and mBC were isolated at different time points by single-cell FACS fol-
lowed by RT-PCR and amplification of IgH variable and constant chain gene rear-
rangements. 
After primary immunization between days 14-18, a total of 207 functional IgH se-
quences from circulating primary KLHspec PB could be obtained. In these KLHspec PB 
a predominance of the Ig alpha-1 constant heavy chain region (Cα1) usage was de-
tectable during all days, i.e. 42% - 90% of the sequences used the Cα1, apart from 
HD2 on day 14 (Figure 5-8 A). Only in 3 of the 5 donors we found KLHspec PB using 
the Cµ (26 from 207 sequences). IgG subclass usage varied within and between do-
nors with yet frequent emergence of sequences using Cγ1 and Cγ2. Although we fre-
quently detected Cγ sequences, the relative molecular isotype distribution of the 
circulating KLHspec PB did not correspond well with the relative IgG to IgA isotype 
ratio of the serologic data (Figure 5-8 B). Nevertheless the somewhat surprising but 
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consistent appearance of IgA on the serologic and molecular level provides a very 
interesting finding for this systemic response, without intended or identifiable mucosal 
contribution (see section 5.1.8). The underlying mechanisms and nature of the Cα 
class-switch remain to be delineated (145-147).  
 
Figure 5-8 IgH sequence isotype usage of KLHspec PB and mBC.  
A Pie charts of the heavy constant chain isotype distribution of KLHspec PB and mBC on indicated days 
after primary (HD1-HD5) and secondary immunization (HD1-HD3). Numbers in circles denote the 
number of productive sequences included. B Ratio of anti-KLH IgG to IgA levels from mean serum 
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antibody (ab) titers (from days 14-24 after primary immunization) and KLHspec PB IgH sequences 
(mean of each isotype from primary PB). C Ratio of anti-KLH IgG to IgA levels from serum antibodies 
and KLHspec PB IgH sequences, 7 days after secondary immunization. 
 
Seven days upon secondary immunization, individual circulating KLHspec PB were 
again isolated using single-cell FACS for sequence analysis. Here, from the three 
donors, in total 92 sequences could be recovered. Again the Cα1 was employed by a 
large proportion of these PB (38%-53%), however, we detected a more frequent us-
age of IgG isotype subclasses (41%-57%) including an increased Cγ1 usage. Yet, 
the ratio of the IgG to IgA isotype usage again did not correspond with the relative 
serum levels of anti-KLH IgG to IgA antibodies (Figure 5-8 B). 
5.1.8 Adhesion receptor profile of the circulating KLHspec PB 
To gain cues on the circulating KLHspec PBs’ origin, which expressed IgA1 to a large 
proportion, the PB were analyzed for their α4β7 integrin and CD62L homing and ad-
hesion receptor profile (Figure 5-9). The homing receptor α4β7 integrin is typically 
expressed on cells activated in the intestinal mucosa, which is associated with IgA 
expression on B cells. Thereby the α4β7 integrin homing receptor supposedly guides 
circulating cells back into mucosal tissues (148). CD62L (L-selectin) is expressed on 
cells activated or generated in the non-mucosal periphery (i.e. parenteral) and guides 
the cells to peripheral lymph nodes (149-151). In humans, it has been shown that 
mucosally activated circulating PB expressed α4β7 integrin to 99% with only a minor 
fraction co-expressing CD62L. In contrast, parenterally induced circulating PB literally 
all expressed CD62L and up to 50% of these co-expressed also α4β7 integrin (152, 
153). Here, the phenotypic analysis of the circulating PB revealed that the majority of 
the primary KLHspec PB carried a systemic adhesion receptor profile, i.e. 65-97% of 
day 14-24 KLHspec PB expressed CD62L and 0-47% of these co-expressed α4β7 
integrin while only a minor fraction expressed α4β7 integrin without CD62L co-
expression. The proportion of the latter fraction does not correspond to the frequen-
cies of Cα1 expressing PB. Thus, the circulating KLHspec IgApos PB were most likely 
not of mucosal origin.  
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Figure 5-9 Homing receptor expression of circulating KLHspec PB after primary immunization. 
Phenotypic analysis of α4β7 integrin and CD62L expression of circulating primary KLHspec PB on indi-
cated days after primary parenteral KLH immunization in donors HD2, HD3 and HD4. 
5.1.9 Isotype usage of circulating KLHspec mBC showed only little over-
lap to primary and secondary KLHspec PB  
2.5 months after primary immunization KLHspec mBC were isolated by single-cell 
FACS from donors HD1-HD3 and their IgH sequence characteristics analyzed. Here, 
from the 3 donors in total 36 single-cell sorted KLHspec mBC IgH sequences were 
recovered (Figure 5-8 A). For HD1 and HD3 we found that the IgH isotype usage dif-
fered to that observed for KLHspec primary and secondary PB, i.e. more pronounced 
Cγ1 chain and reduced Cα1 usage. Notably, in HD1 we found KLHspec mBC using 
Cµ. Although this is so far only an isolated finding, the principle presence of IgM mBC 
in parallel to switched mBC both specific to the same TD antigen could be a hint that 
in humans a similar labour division of mBC subsets exists as has been discussed for 
the murine mBC compartment (154, 155). Thereby IgM mBC are thought to play a 
role in maintaining the mutational flexibility of the memory repertoire by being poised 
to re-enter into the GC response upon re-challenge, contrasting the behaviour of 
switched mBC which were shown to generate PB more vigorously upon re-exposure 
(155). 
5.1.10 VH and JH segment repertoire usage  
A major structural restriction in the reactivity of an antibody towards an antigen lies in 
the employed variable region gene segments, wherefore the KLHspec IgH variable 
region gene repertoire was investigated in more detail. This analysis comprised the 
description of VH- and JH segment and family usage and pairings for each donor, cell 
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type and day post vaccination. The VH and JH usage was further compared with the 
VH and JH repertoire of peripheral blood naïve B cells described by Wu et al. (156).  
As a result, we found that in all donors and KLHspec PB and mBC, respectively, seg-
ments of either the VH3 or VH4 families were used most frequently, i.e. by more than 
66% of all rearrangements (Figure 5-10). 
 
 
Figure 5-10 VH family usage within the expressed variable heavy chain regions from  
KLHspec B cell subsets. 
Distribution of VH family segment usage for KLHspec PB pooled for each donor from all respective sam-
pled days after primary immunization (left), from KLHspec mBC isolated 2.5 months post primary im-
munization (middle) and from day 7 KLHspec PB after secondary immunization (right). For orientation 
frequencies of VH usage from naïve B cells* are additionally shown, from Wu et al. 2010 (156).  
 
In relative terms, for VH1, VH3 and VH4 usage differences to the naïve B cell reper-
toire appear only of minor nature. Yet, employing a χ² goodness-of-fit-statistical test 
to compare the individual used VH distributions (absolute numbers) with the VH seg-
ment usage distribution of naïve B cells (156) revealed that KLHspec B cells differed 
significantly from the naïve B cell repertoire in this aspect (p<0.001 in all cases) es-
pecially in conjunction with the fact that VH6 and VH7 family segments were not used 
in any of the KLHspec IgH variable regions in contrast to naïve B cells. Hence this 
analysis indicated general selection of the KLHspec B cell repertoires.  
In HD1 and HD2, significant variations between the different KLHspec B cell pools 
were observed, i.e. in HD1, secondary PB exhibited a significant different VH distribu-
tion compared to primary PB (pχ²<0.001) while mBC did not. In HD2, both mBC and 
secondary PB differed in their VH family usage distribution from the primary KLHspec 
PB (both pχ²<0.001) suggesting ongoing selection processes during the responses.  
A more detailed analysis of the individual VH segments employed in the KLHspec PB 
and mBC sequences revealed that the KLHspec B cell clones were not randomly se-
lected from across the entire gene locus repertoire but appeared to distribute in a 
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biased fashion, i.e. some segments were overrepresented while others were not 
used at all (Figure 5-11).  
 
 
Figure 5-11 VH segment usage within the expressed variable heavy chain region genes from  
KLHspec B cell subsets.  
Distribution of VH segment usage from KLHspec donor-individual pooled primary PB, mBC and second-
ary PB, respectively. 
 
Due to the partial presence of only one sequence employing the one or other seg-
ment further statistical calculations were not carried out at this point. Noteworthy 
though is the repeated presence of VH3-07 and VH3-48 segments in primary KLHspec 
PB consistent in all donors, while secondary KLHspec PB still employed VH3-07 but no 
VH3-48 segments in their sequences, i.e. VH3-48 segments apparently underwent 
negative selection in the course of the KLH (re-challenge) response. 
Results 
52 
 
Analysis of the JH family usage revealed that all of the known functional JH family 
genes were employed in the KLHspec B cell repertoire (Figure 5-12). The relative 
overall JH gene segment usage followed the general distribution of the relative seg-
ment family usage of a naïve B cell repertoire, i.e. JH4 segments (JH4) were the most 
frequently used JH segments, apart from HD2 day 78 KLHspec mBC, where JH6 was 
found to be used most often (50%) followed by the JH4 (20%) segments. Yet, em-
ploying a χ² goodness-of-fit test again to compare the individual used JH distributions 
with the JH segment usage distribution of naïve B cells (156) revealed that KLHspec B 
cell subsets from all donors exhibited significant differences in this regard to the na-
ïve B cell repertoire (pχ²<0.001 in all cases). Furthermore, comparably to the VH 
segment family usage in HD1, KLHspec mBC exhibited a significantly distinct distribu-
tion compared to primary PB (pχ²<0.01) as well as secondary PB (pχ²<0.001). Also in 
HD2, the mBC showed a significant different JH distribution compared to primary PB 
(pχ²<0.001) while secondary PB did not.  
However, as the number of sequences and experiment repetition is small, the statis-
tical power of these χ² tests is limited and precludes firm conclusions. Thus this data 
can only serve as an indication that selection of the KLHspec B cell repertoire occurred 
and was presumably re-initiated during the re-challenge. 
 
 
Figure 5-12 JH family usage within the expressed variable heavy chain regions from  
KLHspec B cell subsets. 
Distribution of JH family segment usage for KLHspec PB pooled for each donor from the sampled days 
after primary immunization, from KLHspec mBC and secondary PB. For orientation frequencies of JH 
usage from naïve B cells* are additionally shown, *from Wu et al. 2010 (156). 
 
Analyzing the recombination of VH to JH segments revealed that members of the VH3 
gene family were recombined with JH1, JH3, JH4, JH5 and JH6 gene segments, re-
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spectively, all to a comparable extent while members of the VH4 family were most 
frequently found in combination with JH4, JH5 or JH6. 
 
Figure 5-13 Heatmaps of VH to JH family segment combinations used by KLHspec PB and mBC 
after primary and secondary immunization.  
PC = KLHspec PB; d= day. The heatmaps were generated using R (pheatmap-package; euclidean dis-
tance and hierarchical clustering (complete) were used (131, 157)). 
5.1.11 Simultaneous presence of low and highly mutated primary KLHspec 
PB sequences 
Next, to gain insights into the maturation status of the response, the frequency and 
imprints of SHM in the VH regions (FWR1 through FWR3) as compared to their pre-
dicted germline gene sequences were examined. The results are shown in Table 5-1 
and Figure 5-14 A.  
Table 5-1 Summary of molecular properties of expressed IGH sequences of KLHspec B cells. 
Donor
Day post 
immunization
KLHspec B 
Cell Type
Sequences
 mutated %
Number of 
mutations 
per VH 
region 
median 
(range)
accumulated 
R/S ratio 
CDRH1&2
accumulated 
R/S ratio 
FWR 1-3
Total 
number of 
nucleotides
Total 
number of 
mutations
Median 
mutation 
rate***
Number of 
sequences
Number of 
unique 
sequences 
(clones)
HD1 14 PB 100 7 (1-25) 5.4 1.7 8283 306 0.00074 37 18
HD1 15 PB 93 19.5 (0-32) 9 1.6 6780 480 0.00198 30 19
HD1 17 PB 100 25 (5-28) 28.5 1.8 2226 199 0.00215 10 5
HD1 18 PB 100 20 (5-25) 4 1.5 1362 104 0.00161 6 4
HD1 73 mBC 91 9 (0-19) 4 1.3 2469 100 n/a 11 11
HD1 7* PB 100 18 (9-62) 3.6 1.5 12168 1027 n/a 54 49
HD2 14 PB 100 9 (8-24) 1.5 1.8 2616 158 0.00106 12 5
HD2 16 PB 100 15 (3-29) 3.6 1.5 5357 378 0.00139 24 12
HD2 78 mBC 100 16 (7-26) 4.8 2.1 2181 158 n/a 10 9
HD2 7* PB 100 14 (7-30) 4.5 2 4623 321 n/a 21 17
HD3 14 PB 100 26 (3-46) 3.9 1.7 1578 180 0.00276 7 6
HD3 16 PB 100 12 (2-22) 4.8 1.5 3819 210 0.00109 17 15
HD3 78 mBC 100 6 (4-17) 5.4 2.2 3351 125 n/a 15 14
HD3 7* PB 100 13 (6-47) 4.7 1.7 3756 273 n/a 17 14
HD4 18 PB 77 8 (0-40) 2.4 1.7 12857 453 0.0006 57 32
HD5 18 PB 29 0 (0-21) n.a.** n.a.** 1620 30 0 7 7
*** mutations/bp/generation 
(with 8 hours cell cycle)
** no silent mutations were observed.* days post secondary immunization
 
This analysis revealed that 187 out of 207 IgH gene rearrangements obtained from 
primary KLHspec PB, i.e. 90%, were mutated. Only few unmutated sequences were 
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found in donors HD1, HD4 and HD5. The decrease and increase of average SHM 
between the days did not allow deduction of a universal pattern. In detail, in HD1 and 
HD2 an increase of the median mutation frequency from day 14 to days 15-18 to 
relatively high average mutation frequencies of 8.7%-11% (HD1, days 15-18) and 
6.7% (HD2, day 16), respectively was found. In contrast, in HD3, the median muta-
tion frequency decreased from day 14 (11.6%) to day 16 (5.3%).  
Nevertheless, a striking universal pattern regarding the presence of highly mutated 
sequences among these primary KLHspec PB was identified in all donors, i.e. 36% of 
the primary PB sequences carried 15 mutations or more (mutation frequency ≥ 7%) 
in their expressed VH region genes. Such high mutation frequencies were found to be 
largely independent of the underlying isotype, with the exception of the in total 5 VH 
transcripts from Cγ3 and Cγ4 rearrangements that were completely unmutated 
(Figure 5-14 B).  
Next, the pattern of SHM was further analyzed. Antigen-driven selection of the anti-
gen-binding variable region of the BCR in the framework of a GC reaction influences 
the pattern of SHM. Of interest here is a comparison of the ratios of replacement (R) 
to silent (S) mutations in the FWR and the R/S ratio in the CDRH which provides in-
sight into selection processes. The FWR R/S ratio should decrease and the CDRH 
R/S ratio should increase as the GC reaction proceeds and functional selection on 
the basis of improved antigen binding occurs (158). The pattern of SHM of primary 
KLHspec PB IgH sequences sampled over several days fit this hypothesis of antigenic 
selection, i.e. in HD1-HD3 CDRH R/S mutation ratio progressively rose from day 14 
to day 16 or day 17, respectively (Table 5-1) and primary KLHspec PB FWR R/S ratios 
were generally smaller than R/S ratios from CDRH (CDRH1 and CDRH2), with the 
exception of day 14 PB from HD2.  
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Figure 5-14 Somatic hypermutation within VH segments of KLHspec PB and mBC.  
A Frequencies of SHM within VH regions (FWR1-FWR3) from individual KLHspec PB or mBC for each 
donor on indicated days (d). Mann-Whitney tests were performed with p≤0.001 represented by ***, 
p≤0.01 represented by ** and p>0.05 considered as no significant difference (ns). For reasons of visu-
al clarity, only significant differences revealed by testing are indicated for HD1 and HD3 while for HD2 
no significant differences were found at all. B Mutation frequencies for each VH according to its corre-
sponding IgH isotype subclass of primary KLHspec PB were pooled from all donors for this graph. 
 
5.1.12 Mutation rate of the highly mutated primary KLHspec PB 
The simultaneous occurrence of un- to low mutated primary KLHspec PB sequences 
together with the highly mutated sequences, of which the latter comprised approxi-
mately one third of the primary KLHspec PB repertoire, prompted the investigation 
whether the highly mutated PB could be generated from naïve B cells within 2-3 
weeks under the known pre-requisites, i.e. a SHM rate ranging from 4x10-4 to  
1.1x10-3 mutations per bp per division (159-163) and general cell division times be-
tween 6 hours to 18 hours (24, 129, 164). More detailed analyses of the actual mu-
rine GC B cell division time arrived at estimates between 6-8 hours (129). 
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Accordingly, a hypothetical maximum mutation rate for each primary PB sequence 
was calculated, based on the number of mutations observed per analyzed nucleo-
tides, i.e. VH sequence length, on the respective day (Figure 5-15 and Equation 1). 
Assuming 8 hours per cell cycle the calculation revealed that 22% of the primary 
KLHspec PB IgH sequences would have been exhibited to mutation rates of 2x10-3 
mutations/bp/generation or higher corresponding to at least two times higher muta-
tion rates than the maximum rates described (Figure 5-15 A). Moreover, this calcula-
tion also showed that on 8 out of the 10 sampling time points from all donors, the 
average mutation rate of the primary PB was above that of 1x10-3 muta-
tions/bp/generation, when the unmutated PB were excluded, accordingly to the cal-
culations described in the literature (Figure 5-15 B). Even when unmutated PB were 
included this notion was still true for 7 out of the 10 sampling time points (not shown).  
 
 
Figure 5-15 Mutation rate of primary KLHspec PB.  
A Calculated hypothetical mutation rates from individual KLHspec primary PB sequences determined 
from the number of mutations per analyzed nucleotides (bp) of the respective VH segment with an 
assumed cell cycle length of 8 hours (hrs). For orientation, a previously described and later confirmed 
mutation rate is shown by the dotted line, i.e. 1x10-3 mutations/bp/generation (159, 163). Brackets and 
frequencies indicate percentage of sequences that theoretically underwent mutation rates higher than 
1x10-3 (43%) or 2x10-3 (22%) mutations/bp/generation. Unmutated sequences were included in calcu-
lation of the average rate. B Mutation rates calculated as under A, but day and donor individual shown 
for the mean calculation whereby unmutated sequences were excluded.  
Bar indicates mean ± standard deviation. 
 
Importantly, these calculations refer to peripheral blood PB and not to GC B cells, for 
which the previous rates were inferred. Furthermore these calculations do not con-
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sider any lag phase or time for GC-, division- or SHM onset nor any kind of selection 
factor, time for PB differentiation or for tissue egress. Thus the calculated rates will 
underestimate the actual rates required to obtain the numbers of mutations observed. 
In consequence, mutation frequencies and rates of at least 22% of these primary PB 
are inconsistent with prior described observations and assumptions. Unless there are 
unknown or missing assumptions, e.g. mutation rates in humans could be generally 
higher than in murine B cells which however would in turn be inconsistent with the 
simultaneous presence of the low and highly mutated primary PB on the same days, I 
put forward the hypothesis that the highly mutated primary PB are the progeny of 
presumably cross-reactive mBC recruited into this response. 
5.1.13 SHM from the primary- to the memory- to the secondary repertoire 
did not follow a gradual increase  
The circulating KLHspec mBC 2.5 months after primary immunization from HD1 and 
HD3 lacked highly mutated sequences (Figure 5-14 A and Table 5-1) either suggest-
ing that the mBC precursors left the GC response earlier than the PB precursors or 
that the progenitors of the highly mutated primary PB sequences could not compete 
with the lower mutated sequences and were deleted from the repertoire. More de-
tailed sequence repertoire analyses will permit more subtle insights into these as-
pects.  
Upon secondary immunization, all VH sequences were found somatically mutated. 
However, in HD2 and HD3, compared to primary KLHspec PB no significant increase 
of the median mutation frequency and number could be detected whereas in HD1 the 
average increase of somatic mutations was significant (Mann-Whitney test, p<0.001; 
Figure 5-14 A). Whether this increase comprised additional SHM within VH sequenc-
es of PB detected during primary immunization, i.e. indicative of SHM re-initiation 
upon re-challenge, or whether the secondary response comprised an underlying dif-
ferent sequence repertoire will also be revealed by a more detailed analysis of the 
primary PB, mBC and secondary PB clonal repertoires (see below).  
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5.1.14 Circulating primary KLHspec PB repertoires showed within donor 
between day variations  
We next studied the KLHspec IgH sequences for their CDRH3 length distribution 
(Figure 5-16) as restricted antigen-specific antibody responses have been shown to 
select for CDRH3 loops of particular lengths (45, 165, 166). Moreover the CDRH3 
region allows first conclusions on the clonality of an immune response.  
For the primary KLHspec PB it was thereby apparent that a broad range of CDRH3 
lengths was found, with donor-specific values for minimum and maximum lengths, 
overall ranging from 18 to 78 bp, indicative of a relatively unrestricted response. 
However donor-specific accumulations of certain lengths could be identified, partly 
resulting from clonally related cells (described below). As the CDRH3 region is the 
main site of specific contact between the antibody and the antigen, it is reasonable to 
assume that similar antigenic recognition sequence patterns may be present in be-
tween the donors at this site. Therefore a search for sequence motifs within CDRH3 
regions was conducted using the MEME suite, ClustalW and Weblogo (125-128). 
However, no common amino acid sequence motifs could be identified, neither be-
tween KLHspec CDRH3 sequences within a donor nor across donors (data not 
shown). 
 
Figure 5-16 CDRH3 sequence lengths of KLHspec primary PB, mBC and secondary PB.  
Distribution of CDRH3 lengths in base pairs (bp) of KLHspec B cell subsets for each donor and day (d) 
as indicated. Bar indicates median. Mann-Whitney tests were performed with p≤0.01 represented by ** 
and p>0.05 considered as no significant difference (ns). For reason of visual clarity, only significant 
differences revealed by testing are indicated for HD1 and HD2 while for HD3 no significances were 
found at all. 
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As the distribution of the CDRH3 lengths of KLHspec primary PB indicated oligo- to 
low order polyclonal repertoires with a certain underlying day-wise exchange of the 
circulating pools (Figure 5-16) the IgH sequences were further analyzed for clonally 
expanded cells. A clone was defined by its unique IgH variable region sequence in-
cluding the CDRH3 length and sequence, as described by us before (38). This analy-
sis identified trees of clonally related and expanded PB and mBC within the KLHspec 
B cell pools of HD1-HD4 and no sequences qualifying as clonally related were found 
between individual donors. Pies of the circulating KLHspec primary PB, mBC and sec-
ondary PB repertoires are shown in Figure 5-17. 
 
Figure 5-17 Donor individual KLHspec B cell clone repertoires and relationships through the 
KLH response.  
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Pie charts representing the different clonal families of KLHspec PB and mBC. White slices denote those 
sequences found only once during the entire response. Circled number within each pie chart denotes 
the total number of sequences and slices are unique clones and proportional to clone size. Numbers 
underneath the pies are the one-sided 95% confidence limits of the maximum likelihood estimates of 
the statistical repertoire sizes, calculated with the Stirling’s numbers of the second kind, as described 
before (130). A Pies of donor individual pooled primary PB are shown for days 14-18. KLHspec PB se-
quences found only once between days 14-18 of that yet clonally related cells were found in the KLH-
spec mBC or secondary PB compartment were also marked by a color piece. B Day-wise primary clonal 
repertoires for HD1 – HD3.  
Pie charts of KLHspec mBC are shown under C and for KLHspec secondary PB under D. 
  
As has been already indicated by the CDRH3 length distribution for HD1 - HD3, the 
detailed sequence repertoire analyses revealed a within donor between day variation 
for the primary KLHspec PB (Figure 5-17 A and B). To support this notion further a 
statistical prediction of the theoretical repertoire sizes based on the isolated reper-
toires was made using a statistical repertoire size estimation, as described (130). 
With this approach a maximum likelihood estimate n (P(d)max) for each donor and day 
and a 95% one-sided confidence limit n (P(d)<0.05; Table 5-2) could be calculated. To 
shortly explain, d is the number of distinct gene rearrangements, r is the number of all 
examined gene rearrangements and n is the theoretical statistical calculated quantity 
of different clones within one individual, to ensure the empirical found numbers of 
observed distinct sequences among all of the examined sequences (see Equation 2).  
This calculation yielded differing daily repertoire sizes (i.e. rearrangement events) 
and thus supported the suggestion that the circulating primary PB were partially ex-
changed between the sampled days (Figure 5-17 B and Table 5-2).  
Table 5-2 Statistical calculations of repertoire sizes 
Donor Day post immunization Cell Type P(d)<0.05  for n= P(d)max for  n= d r
HD1 14 PC 29 21 18 37
HD1 15 PC 46 29 19 30
HD1 17 PC 13 5 5 10
HD1 18 PC 33 6 4 6
HD1 73 mBC n/a n/a 11 11
HD1 7 PC 2930 270 49 54
HD2 14 PC 10 5 5 12
HD2 16 PC 22 14 12 24
HD2 78 mBC 865 42 9 10
HD2 7 PC 122 45 17 21
HD3 14 PC 405 19 6 7
HD3 16 PC 338 64 15 17
HD3 78 mBC 2007 100 14 15
HD3 7 PC 136 41 14 17
HD4 18 PC 55 43 32 57
HD5 18 PC n/a n/a 7 7  
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5.1.15 Largely unrelated circulating KLHspec primary, memory and sec-
ondary B cell repertoires  
Next, also KLHspec mBC and secondary PB were analyzed for their clonal composi-
tion. For HD2 and HD3, one mBC was found for each donor of which a related se-
quence was isolated already from the respective circulating primary PB pool. For 
HD1, four related KLHspec mBC of which primary PB clones existed were found 
(Figure 5-17 C). Thus, in conclusion the majority of primary KLHspec PB clones were 
not reflected in the analyzed circulating KLHspec mBC, which interestingly appeared to 
be more poly- than oligoclonal in comparison to the primary PB repertoire. 
From the secondary PB sequences we could retrieve in total 4 clones that were re-
lated to primary PB. Thus clonal relationships between the secondary and primary 
repertoire were even more infrequent than from the primary to the mBC repertoire 
(Figure 5-17 D). Further, only in HD1 and HD2 individual secondary PB sequences 
were found that were related to the analyzed mBC after 2.5 months. Hence, the sec-
ondary KLHspec PB repertoire exhibited a considerable deviation to the KLHspec prima-
ry PB and mBC repertoire (Figure 5-17). Notably, theoretical repertoire size 
calculations revealed for HD1 and HD2 more diverse secondary KLHspec PB (progeni-
tor) repertoires compared to the primary KLHspec PB.  
In summary, these analyses disclosed largely different circulating KLHspec B cell rep-
ertoires between the primary and secondary effector cells and the steady state mBC, 
as illustrated in Figure 5-18. 
 
Figure 5-18 Venn diagrams of clonal overlap between KLHspec B cell pools.  
The Venn diagrams show clonal overlap of KLHspec primary PB, mBC and secondary PB sequences 
for HD1-HD3. Given are the numbers of unique and overlapping clones in the respective compart-
ment. 
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5.1.16 Absence of a universal affinity maturation and CSR axis within 
clonally expanded KLHspec B cell genealogy trees 
Finally, analysis of genealogic trees of clonally expanded KLHspec B cells in more de-
tail was performed to assess whether individual clones converged toward a single 
(higher mutated) variant on a clonal branch or diverged across multiple options along 
diversification in several branches independently and to uncover potential common 
maturation axes.  
A selection of such trees from HD1 to HD4 is shown in Figure 5-19 a-m. This analysis 
found examples of divergent branches of subclonal variants (a-k) where further diver-
sification (independent of the underlying mutation load) occurred and other examples 
where no such diversification was evident (l,m). Within some of these trees both pos-
sibilities were found (a,b,c,e,i,j,k). 
Also examples of clonally related cells were identified which diverged across antibody 
classes (a,b,c,f,g,j,l,m) and other examples where they did not (d,e,h,i,k) leaving 
room for speculation on switch cues and differentiation environments for equally mu-
tated clones with distinct isotype usage.  
In donors HD1-HD3, where few clonally related KLHspec primary PB and mBC could 
be retrieved (a,b,d,g,i), two examples of mBC that were less mutated than the corre-
sponding PB (a, d) were found whereas in the other examples mBC exhibited a high-
er mutation load (b,g,i).  
In the few cases of clonally-related KLHspec primary and secondary PB some of these 
trees suggested that re-diversification of the precursors may have occurred while 
other examples did clearly not support that notion, including examples of both possi-
bilities even within the same trees (i,h and c,h respectively). 
These results indicate that clonal diversification and selection processes are very 
dynamic and complex for this response. Potentially, larger sampling sizes and more 
sampling time points could help to unravel existent directional maturation axes. The 
data here do not allow conclusions about the latter nor do they provide clarification to 
whether mBC re-enter GC upon reactivation, as the data here are indicative of both 
pathways, i.e. GC-dependent and GC-independent PB generation from mBC.  
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Figure 5-19 Genealogic trees of individual expanded B cell clones.  
Selected genealogic trees of different primary PB, mBC and secondary PB clonally related cells from 
HD1 – HD4, found on indicated days. In donor HD5, no clonally related cells were found. Grey circles 
denote hypothetical logical precursors. The predicted germline sequence is printed above each clone. 
Numbers on branches indicate numbers of shared mutations of the successive cells. Isotype printed 
within the circles are the isotype of the respective cell. Blue circles: KLHspec PB sequence. Orange 
circles: KLHspec mBC sequence. 
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5.2 Tissue distribution and related phenotype of human 
memory B cells 
One result from the previous investigation was that primary KLH immunization in-
duced an immunological memory. For the B cell memory compartment such memory 
consists of long-lived PC and mBC. Whereas it is acknowledged that long-lived PC 
preferentially reside in niches in the BM (65, 68) as well as in spleen (67, 86) and 
tonsil (87, 167), little is known about potential survival niches for mBC and the role of 
certain organs in mBC maintenance and functionality. To address this question a 
comprehensive mapping, including quantification and phenotyping of mBC within dif-
ferent lymphoid organs, i.e. spleen, BM and tonsil compared to peripheral blood, dur-
ing steady state conditions was conducted. Furthermore, effects on circulating mBC 
proportions potentially resulting from the absence of spleen and tonsil, respectively, 
were investigated. 
5.2.1 Tissue-specific compartmentalization of human B cells 
To gain a first overview of the general lymphocyte subset composition in humans, the 
tissues under study were analyzed for their relative CD19pos B cell to CD3pos T cell 
content (Figure 5-20).  
 
Figure 5-20 B cell and T cell proportion is intrinsic to the tissue.  
Shown is the ratio of B cell:Tcell numbers determined by flow cytometry from isolated mononuclear 
cells from the tissues (blood n=15, BM n=14, spleen n=7, tonsil n=11), given as median ± interquartile 
range.  
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Whereas spleen and tonsil contained similar numbers of B and T cells with a tenden-
cy of higher B cell than T cell numbers in the spleen, the amount of T cells outnum-
bered that of B cells in blood by 6.5- to 23-fold and in BM by 0.7- to 4.3-fold, for the 
latter including one example where the T cell number was below that of the B cell 
number. 
Subsequently, a detailed assessment of B cell frequencies was conducted and is 
shown in Figure 5-21 A. A relative enrichment of CD19pos B cells was found in the 
BM (median 19%), spleen (33%) and tonsil (43%) compared to those circulating in 
peripheral blood (4%). This relative distribution was transformed into absolute B cell 
numbers, based on lymphocyte numbers per organ as described (121). This approx-
imation yielded highest B cell content in spleen, followed by 2.5- to 3.5-fold less B cell 
numbers in BM and tonsil, respectively, which all contained substantially higher (20- 
to 70-fold) total numbers of B cells than blood. 
 
Figure 5-21 Distribution of B cells in blood and different lymphoid organs.  
A Isolated mononuclear cells from human peripheral blood (n=16), BM (n=25), spleen (n=8) and tonsil 
(n=20) were analyzed for their frequencies of CD3negCD14negCD19pos B cells from living scatter gated 
lymphocytes. B Transformed absolute numbers of those CD19pos B cells in the different tissues based 
on the ratio of gated B cells to all lymphocytes, multiplied with absolute lymphocyte numbers of the 
respective tissue as previously described by Trepel (121). Bar indicates median ± interquartile range. 
 
Next, the B cell population within each tissue was analyzed regarding its subpopula-
tion constitution (Figure 5-22) with a focus on mBC subsets. Depending on the type 
of tissue of interest, a variety of markers can be selected to define the specific B cell 
subsets. For tonsil and later also for blood for example, the B mature classification 
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was used defining B cells according to their activation and differentiation stages 
based on the surface expression of CD38 and IgD (101, 168). However, for other 
tissues, e.g. BM and spleen, this system has not been validated. Another widely used 
B cell classification is by surface expression of CD20 and CD27. CD27 is regarded 
as a pan-mBC marker as it has proven its usefulness in separating reactive antigen-
experienced non-cycling B cells from mature naïve B cells and antibody-secreting 
PB/PC (91, 143, 144, 169-172). Further, the resolution of this system can be consid-
erably enhanced with regard to IgD expression, i.e. mBC can be divided into IgDpos 
and IgDneg subsets (173) and a small population of CD27negIgDneg mBC can be de-
termined (174, 175), amongst other. As the B mature classification impedes analysis 
of these various (blood) mBC subsets, in this study the CD20/CD27 classification 
was used.  
 
 
Figure 5-22 B cell subset frequency within the different tissues.  
CD19posCD3negCD14neg B cells isolated from blood (n=15), BM (n=14), spleen (n=7) and tonsil (n=11) 
were separated by their CD20 and CD27 expression. A Representative dot plots from flow cytometry 
analysis with indicated gating areas, starting in the lower left corner, clockwise: CD20negCD27neg  cells 
(black circle), CD20negCD27pos cells (khaki), CD20neg/lowCD27high  cells (yellow), CD20posCD27pos cells 
(orange), CD20highCD27int cells (grey) and CD20posCD27neg cells (purple). B Frequency of B cell subset 
distribution within the different tissues, given as mean ± standard deviation. 
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For the general B cell analysis this staining revealed at least 6 CD19pos B cell sub-
sets, i.e. CD20negCD27neg cells, CD20negCD27pos cells, CD20neg/lowCD27high  cells, 
CD20posCD27pos cells, CD20highCD27int cells and CD20posCD27neg cells, for which tis-
sue-specific patterns could be identified. 
In detail, spleen and blood contained in their majority three main B cell populations, 
i.e. CD20posCD27neg cells, comprising naïve B cells in their majority but also transi-
tional B cells and few mBC, CD20posCD27pos cells which are considered as mBC in 
their large majority and CD20neg/lowCD27high cells, which are acknowledged to be an-
tibody-secreting PB and PC in their majority. In addition to those three B cell subsets, 
tonsils contained a CD27intCD20high B cell population which resembled a GC B cell 
phenotype, confirmed by their high expression levels of CD38 and negativity for 
CD24 (not shown) as described elsewhere (71, 176). This subset was also traceable 
in spleens from young adults but largely absent in spleens from elderly. In addition to 
the former three populations, BM contained two largely exclusive populations. One 
prominent population with the phenotype CD20negCD27neg, which presumably are B 
cell precursor stages and a smaller population of CD27intCD20neg cells which are of 
unknown identity so far. 
5.2.2 Defining a mBC gating strategy 
The composition of the B cell populations within the different tissues revealed a 
CD20negCD27int B cell subset within BM of which the origin and potential relationship 
to the mBC compartment is currently unknown. Therefore, as mBC can classically be 
defined as class-switched (small and quiescent) B cells, IgG and IgA expressing B 
cells, respectively, were mapped for their localization in the CD20/CD27 system. This 
was carried out to test whether the BM CD20negCD27int B cells may constitute a 
(class-switched) mBC population (Figure 5-23).  
This analysis identified IgApos and IgGpos class-switched B cells in the 
CD20highCD27int, CD20neg/lowCD27high and in the CD20posCD27pos population but not 
in the BM CD20negCD27int B cell population. This does not exclude its mBC identity 
but prompted us to exclude them from our mBC analysis at this point as further stud-
ies will be required to determine their origin. As a result, in the following analyses 
mBC were identified as CD20posCD27pos B cells in all tissues. 
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Figure 5-23 Mapping of IgA and IgG B cells in the CD20/CD27 classification.  
A Dot plots of gating for IgA- (left; pink marked cells) and IgG- (right, green marked cells) surface ex-
pressing B cells. B Representative dot plots of mapping the as under A gated IgA (pink, upper row) 
and IgG (green, lower row) B cells, respectively, in the CD20/CD27 classification. 
 
5.2.3 Distribution of human mBC in different lymphoid organs  
Subsequently, frequencies of mBC among CD19pos B cells were determined. This 
analysis yielded an on average higher frequency of mBC detected in the spleen 
(46%) as compared to peripheral blood (30%) and tonsil (21%), whereas the BM con-
tained a substantially lower mBC frequency (8%; Figure 5-24).  
With respect to approximated absolute numbers, significantly more mBC were found 
in the spleen and tonsil (median 9.1x109 and 1.1x109, respectively) compared to pe-
ripheral blood (8.2x107) and BM (6.6x108). This equals 111-fold enrichment of mBC 
in spleen compared to blood, and 14- and 8-fold more mBC in spleen compared to 
BM and tonsil, respectively. 
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Figure 5-24 Tissue distribution of human mBC.  
A Isolated mononuclear cells from human peripheral blood (n=16), BM (n=25), spleen (n=8) and tonsil 
(n=20) were analyzed for their frequencies of CD20posCD27pos mBC within CD3negCD14negCD19pos B 
cells. B Transformed absolute numbers of mBC in different tissues.  
Bars and numbers indicate median, respectively, error bar is the interquartile range. 
 
5.2.4 Age dependence of mBC accumulation within the tissues 
We further investigated whether an age dependence of mBC frequency in the differ-
ent tissues under study existed (Figure 5-25). Notably, we did not have access to 
samples from children under the age of 10 years for our analyses. In this regard it is 
important to acknowledge that blood CD27pos B cells increase gradually with age, 
most prominent during the first 10-15 years of life (170).  
The results from our analysis show that during adulthood, throughout 35 to 82 years 
of age, mBC frequencies remained low in BM whereas the spleen constantly con-
tained a high proportion of mBC, for ages ranging from 16 – 79 years, with one ex-
ception. For both tissues, no significant linear age-mBC frequency dependence could 
be found using the Spearman's rank correlation test. In blood the frequencies of mBC 
varied considerably between the individuals with ages ranging between 23 and 63 
years, and also no linear age-mBC frequency dependence was detectable, which 
was also true for tonsil.  
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Figure 5-25 Age dependence of relative mBC accumulation within the tissues.  
Relation of donor age to mBC frequency for peripheral blood (n=40), BM (n=34), spleen (n=10) and 
tonsil (n=20) samples. No significant correlation was observed in any of the tissues (Spearman's rank 
correlation coefficient).  
5.2.5 Expression of markers associated with tissue residency  
For tissue-resident resting CD4pos memory T cells, different studies identified that 60-
100% of these expressed CD69 whereas in contrast, only few (1-20%) blood memory 
T cells expressed that marker (177) and therefore CD69 was considered as a marker 
for tissue resident T cells. Further, it has been described that CD69 suppresses 
Sphingosine-1-phosphate receptor 1 (S1PR1) and therefore inhibits tissue egress 
(178, 179) consistent with a role of CD69 in lymphocyte tissue retention. Therefore, 
we next analyzed CD69 expression of the tissue-residing mBC in contrast to circulat-
ing mBC (Figure 5-26).  
 
Figure 5-26 CD69 expression of lymphoid organ and blood mBC and T cells.  
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A Histograms of CD69 expression of CD3pos T cells (upper row, shown for comparison only) and of 
mBC (lower row). B Frequency of CD69 expressing mBC (right) and for comparison only, of CD3pos T 
cells. As control (grey histogram) blocking with unlabeled CD69 was performed prior to the staining. 
Bar indicates median.  
 
This analysis demonstrated that with overall 2% -18% of mBC from blood, BM and 
spleen, the minority expressed CD69 in these tissues (Figure 5-26 B). By contrast, 
the majority of tonsillar mBC were CD69pos, with expression found on 57% - 71% 
mBC here.  
Yet, as evident already by visual inspection of the representative histograms (Figure 
5-26 A) the tonsillar mBC CD69-expression level was below that of tissue-residing T 
cells, which was exemplarily analyzed for three tonsillar mBC and T cell pairs (Figure 
5-27). 
 
Figure 5-27 CD69 expression levels of tonsillar mBC and T cells.  
Three tonsils were additionally analyzed for the CD69 median fluorescence intensities (MFI) of 
CD69pos mBC and T cells. Bar indicates median. 
 
Next, as CD69 was originally described to be an immediate early activation marker, 
being rapidly and transiently induced upon T cell activation and was associated with 
lymphocyte proliferation (180), the expression of the proliferation-associated marker 
Ki-67 (181) was investigated as the environment of the tonsil is immunologically far 
more active than that of spleen, BM or blood. Thus the tonsillar CD69pos mBC could 
simply constitute an activated B cell population. However, this analysis showed that 
Ki-67 was generally only expressed in a minor fraction of tissue-residing mBC, i.e. on 
0.5% - 13%, indicative that the identified overall and tonsillar mBC populations are 
indeed mostly quiescent in terms of proliferation (Figure 5-28), in contrast to approx-
imately 50% of the tonsillar GC B cell population (Figure 5-28 A).  
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Figure 5-28 Expression of Ki-67 on tissue-residing and circulating mBC.  
A Proportion of Ki-67pos mBC from their parent population. For comparison only, the tonsillar 
CD20highCD27int B cell population, i.e. GC B cells, is also shown regarding its percentage of Ki-67pos 
cells. Bar indicates median. B Representative dot plots showing Ki-67 and CD69 expression by mBC, 
the rectangle gate marks the co-expressing mBC population. 
 
 
Furthermore, the Ki-67pos mBC population did not co-express CD69 (Figure 5-28 B). 
Hence, it appears likely that the CD69 expression on tonsillar mBC is indeed associ-
ated to tissue retention and these mBC should consequently be non-migratory.  
To investigate this aspect further, expression of CD62L, a molecule involved in active 
lymphocyte recirculation and trafficking, also known as L-selectin, was analyzed 
(Figure 5-29).  
Results 
73 
 
 
Figure 5-29 Expression of CD62L on lymphoid organ and circulating mBC.  
A Representative histograms of CD62L expression on mBC. As control, the isotype staining is shown 
(grey histogram). B Median fluorescence intensities (MFI) of CD62L on tissue and circulating mBC. 
Bar indicates mean. 
 
CD62L was highly expressed on blood mBC (37800 ± 7646; mean MFI ± standard 
deviation), at lower levels on BM (10428 ± 7349) and on tonsillar mBC (6551 ± 3581) 
and exhibited strongly reduced expression on splenic mBC (1024 ± 745; Figure 5-29 
B). Thus tonsillar mBC exhibited reduced CD62L expression in contrast to circulating 
mBC but expressed it well above the level of splenic mBC that are described to be 
recirculating (182).  
The inhibitory receptor receptor-like protein 4 (FcRL4) has been described to be ex-
pressed on human mBC which reside in epithelial tissues (183) and on an mBC sub-
set in tonsils (184). Therefore, the expression of FcRL4 was analyzed to investigate 
whether it identifies a tissue-resident mBC population (Figure 5-30). 
As can be seen in Figure 5-30, the majority of CD20posCD27pos mBC in blood as well 
as in the tissues under study, including tonsils, did not express FcRL4. 
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Figure 5-30 Expression of FcRL4 on tissue and circulating mBC.  
Proportion of FcRL4pos mBC from their parent population. Bar indicates median. 
5.2.6 Differentiation and migration marker expression by human mBC 
obtained from different human tissues  
For tissue-resident long-lived BM PC it has been described that these expressed a 
more mature phenotype compared to tonsillar and blood PB/PC, i.e. decreased ex-
pression of HLA-DR, CD95, CD45 and CD21 among others (167). Following this 
idea, tissue and blood mBC were next analyzed for their expression of markers asso-
ciated to an advanced maturation stage and distinct homing and migration behavior. 
Representative histograms from a series of experiments are summarized in Figure 
5-31 A. The differentiation and activation markers CD24, CD45, CD21 and HLA-DR 
were expressed on almost all mBC, comparably in all tissues analyzed (Figure 5-31 
B) and deviations were detectable on a statistical level but did not lead to disclosure 
of considerable separate negative populations. The ICOSL was expressed at low 
levels on mBC from blood (525 ± 101; mean MFI ± standard deviation) and BM (604 
±135) but was largely absent on mBC from spleen (179 ± 127) and tonsil (134 ± 24; 
Figure 5-31 C). Analysis of lymphocyte trafficking and adhesion markers showed that 
CD54 (ICAM-1) was expressed on almost all mBC from all tissues which was also 
true for CD31 (PECAM-1), yet for the latter the frequencies of mBC from spleen 
(96.5% ± 1.9%) and BM (95.9% ± 1.9%) expressing this molecule was greater com-
pared to those of blood (79.5% ± 6.3%) and tonsil mBC (81.2% ± 4.0%).  
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Figure 5-31 Comparative analysis of the pattern of expression of differentiation, survival and 
migration associated molecules by mBC from different tissues. 
A Representative examples of molecule expression associated to differentiation and activation 
(ICOSL, CD21, CD24, HLADR, CD45), lymphocyte trafficking and adhesion (CXCR4, CXCR5, α4β7 
integrin, CD54, CD31) and survival (CD95) by blood, BM, spleen and tonsil mBC (black line). As con-
trol, corresponding isotype controls are shown (grey). B Frequencies of mBC expressing the markers 
as indicated. C Median fluorescence intensities (MFI) of indicated markers expressed by mBC from 
each tissue.  
Symbols underneath the diagrams indicate significant differences between tissues as indicated by the 
legend (Mann-Whitney tests were performed with p≤0.01 considered as significant difference). Num-
ber of samples ranged between 5-10 for each marker and tissue. Bar indicates mean. Error bars rep-
resent the standard deviation. 
 
The chemokine receptor CXCR5, involved in B cell migration into B cell follicles from 
spleen and Peyer’s patches (185), was homogenously expressed by nearly all mBC 
from all tissues analyzed, apart from a small portion of BM mBC (6.6% ± 3.3%). 
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CXCR4, also involved in lymphocyte follicle positioning and homing behavior to the 
BM (186), was found to be expressed somewhat higher on splenic (MFI 402 ± 262), 
BM (510 ± 270) and tonsillar (791 ± 674) mBC compared to circulating mBC (253 ± 
84). The death receptor CD95 (FAS/APO-1) was expressed at similar low densities 
on the majority of mBC obtained from all tissues. 
Interestingly, the mucosal (gut-) homing adhesion molecule β7 integrin, which can be 
considered as representative for α4β7 integrin expression (187), was found to be 
present on a proportion of mBC from all tissues, yet in tonsil, a mucosal associated 
tissue, a significantly smaller mBC population expressed β7 integrin (29% ± 9%) in 
contrast to mBC from blood, spleen and BM, respectively (54.3% ± 8.9%, 60.7% ± 
9.6% and 61.2% ± 6.2%, respectively). Further analysis of pre- and post-switch mBC 
population revealed that IgDpos mBC expressed significantly higher levels of β7 integ-
rin than IgDneg mBC consistently in all tissues (Figure 5-32). 
 
Figure 5-32 β7 integrin expression levels of IgDpos and IgDneg mBC from the different lymphoid 
organs and blood.  
Median fluorescence intensities of surface expression of β7 integrin on mBC as indicated. Wilcoxon 
signed rank tests were performed. 
 
 
In summary and albeit small detectable differences, none of these yielded identifica-
tion of mBC populations consistent with differential maturation stages or survival ca-
pacities between the different tissues studied. 
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5.2.7 Distinct distribution of IgA, IgG or IgM/IgD-expressing mBC in dif-
ferent tissues 
Next, compartmentalization of different isotype expressing mBC populations including 
CD20posCD27negIgDneg B cells was assessed. The gating strategy of a representative 
example is shown in Figure 5-33 A. 
This analysis demonstrated that circulating and BM mBC contained similar frequen-
cies of surface IgA (median 17.3% and 20.0%, respectively) and IgG expressing 
mBC (22.9% and 22.6%, Figure 5-33 B). In contrast to the other tissues, tonsillar 
mBC contained a larger frequency of surface IgApos mBC (26.1%) whereas surface 
IgGpos mBC were present to similar frequencies in spleen (31.7%) and tonsil (36.6%) 
and thus enriched compared to blood and BM. The pre-switched mBC population 
(IgMpos/IgDpos) was reduced in tonsil (25.6%) compared to the populations present in 
blood (48.9%), spleen (45.0%) and BM (37.9%). Yet, with respect to absolute num-
bers, the spleen contained the largest populations of IgApos, IgGpos and IgMpos/IgDpos 
mBC, respectively (Figure 5-33 D). Notably, tonsils represented a site of relative ac-
cumulation of classic (IgApos and IgGpos) post-switched mBC, whereas pre-switched 
mBC appeared de-enriched. 
As described above and in line with previous reports, within the CD27neg B cell popu-
lation mutated and class-switched B cells, considered to be mBC, can be found in 
blood (174, 175). Therefore, in this analysis the CD20posCD27negIgDneg B cell popula-
tion (double-negative mBC) was included in our BCR-isotype cross-tissue compari-
son (Figure 5-33 C and E). We found that double-negative mBC comprised IgG 
expressing cells in their majority, consistent for blood (median frequency 1.9% of 
CD19pos B cells), spleen (2.6%) and tonsil (1.6%). In contrast, the frequency of IgA 
and IgG double-negative mBC, respectively, appeared more balanced in BM (0.2% 
IgA and 0.5% IgG). In absolute numbers double-negative IgGpos B cells were present 
in higher quantities than double-negative IgApos B cells in all tissues under study 
(Figure 5-33 E). With regard to the CD20posCD27pos mBC, overall absolute numbers 
of both double-negative mBC subsets were 4- to 17-fold less than that of the isotype-
corresponding CD27pos mBC subset (Figure 5-33 D and E).  
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Figure 5-33 Expression of surface isotypes by lymphoid organ and CD27pos circulating mBC 
and CD20posCD27negIgDneg B cells.  
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A Gating strategy for isotype-specific mBC (IgA: i); IgG: ii) and IgM/IgD: iii); all upper row) and for 
CD19posCD20posCD27negIgDneg B cells (IgA: iv) and IgG: v), lower row), exemplarily shown from tonsil. 
B Frequency of IgApos, IgGpos or IgMpos/IgDpos mBC from a series of experiments. Mann-Whitney test, 
**: p<0.01; ***: p<0.001. C Frequency of IgApos and IgGpos CD20posCD27negIgDneg B cells, respectively, 
from CD19pos B cells. D and E Transformed absolute numbers of respective indicated B cell popula-
tions, calculated as described in Figure 5-21. 
 
5.2.8 TTspec mBC are enriched in the spleen followed by tonsil 
In addition to the overall picture of mBC distribution described above, subsequent 
analysis evaluated the presence and distribution of an antigen-specific mBC popula-
tion. Here, TTspec mBC were analyzed exemplarily, as most individuals have been 
immunized against TT. Thus, this specificity could help to reveal whether systemically 
induced mBC distributed in the tissues under study similarly or potentially preferred 
residence within the one or other organ. For this analysis again the direct TTspec B 
cell staining, as described in section 5.1.1, was used. This analysis frequently identi-
fied TTspec mBC in peripheral blood (median on average 0.04%), in the spleen 
(0.04%) and in the tonsil (0.06%). In BM, TTspec mBC could only be infrequently de-
tected (Figure 5-34 A).  
 
Figure 5-34 Tissue distribution of human TTspec mBC.  
A Isolated mononuclear cells from human peripheral blood (n=16), BM (n=22), spleen (n=8) and tonsil 
(n=19) were analyzed for their frequencies of TTspec cells (here TTpos) within 
CD3negCD14negCD19posCD20posCD27pos B cells. B Transformed absolute numbers of mBC in different 
tissues. Bars and numbers indicate median, respectively, error bar is the interquartile range. 
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In absolute numbers (Figure 5-34 B), the spleen accommodated most TTspec mBC 
(median 2.1x106) followed by those prevalent within the tonsil (8.5x105) and blood 
(3.0x104). Their detection in the BM was too infrequent for general conclusions at this 
point.  
5.2.9 Influence of splenectomy and tonsillectomy on circulating mBC  
Since the spleen and tonsil have been found to be very intriguing mBC accommodat-
ing organs, finally, the consequences of absence of spleen or tonsil, i.e. in humans 
either splenectomized or tonsillectomized, on blood mBC homeostasis was investi-
gated (Figure 5-35).  
 
Figure 5-35 Circulating mBC are reduced in splenectomized versus healthy controls and tonsil-
lectomized donors.  
A Representative dot plots of the gating strategy. PBMC were gated with an extended forward scatter 
gate with subsequent exclusion of non-single cells (not shown) and subsequent gating on B cells. 
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Frequencies of mBC (i) and subsequently of IgDpos and IgDneg subsets were analyzed (ii). Upper row: 
Splenectomized patient (S). Middle row: tonsillectomized HD (TX). Lower row: HD. Frequencies of 
mBC (B), IgDneg mBC (C) and IgDpos mBC (D) are expressed as percentage from CD19pos B cells. Bar 
indicates median, error bar is the interquartile range. Grey dot: respective frequencies from splenec-
tomized individual S2 who had the shortest time period after splenectomy (7 months) and considered 
short-term splenectomized in contrast to the other splenectomized individuals. 
 
This analysis clearly showed that four long-term splenectomized individuals S1 (2 
years splenectomized), S3 (35 years), S4 (13 years) and S5 (4 years) exhibited re-
duced frequencies of circulating mBC (11.0%, 9.0%, 1.7% and 14.7% for S1, S3, S4 
and S5 respectively), whereas patients S6 (40 years, long-term splenectomized) and 
S2 (7 months, classified as short-term splenectomized) did not show such a drastic 
change (22.4% and 24.0%, respectively) compared to 10 HD (30.0%; Figure 5-35 A 
and B). In contrast, tonsillectomized individuals (n=10) exhibited no change of circu-
lating mBC frequencies (median 31.8%) in comparison to the HD cohort at all. 
Separate analysis of pre- and post-switch mBC (Figure 5-35 C and D) showed that all 
splenectomized individuals had reduced circulating IgDpos mBC (median 2.2%) in-
cluding S2 (6.7%) and S6 (3.2%) compared to HD (median 14.9%;) and tonsillecto-
mized donors (17.8%), respectively. In contrast, post-switch mBC were reduced only 
to a minor extent in the splenectomized group (median 9.9%) compared to HD 
(14.5%) and tonsillectomized HD (15.0%, Figure 5-35 C). 
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6. Discussion 
The humoral immune response is mediated by B cells and their soluble effector mol-
ecules produced upon antigenic challenge. Such challenges can be of a primary or 
secondary, i.e. repeated, nature and have been shown to consequently elicit distinct 
response kinetics which differ quantitatively and qualitatively. Most of our knowledge 
in this regard derives from animal models and is unfortunately not unlimited transfer-
rable to humans, as we have an approximately 50-times higher life expectancy to-
gether with a more complex immunological history. As many immune system related 
diseases or abnormalities, e.g. autoimmunity and hypersensitivities, appear during 
adulthood a thorough knowledge base of the adults’ immune system and immune 
response mechanisms is of importance not only for a basic understanding but also 
for future therapeutic interventions.  
This study aimed to enhance our knowledge of underlying mechanisms of primary 
and secondary immune responses in human adults as well as of B cell memory in-
duction, maintenance and its reactivation. To achieve this, in the first part a compre-
hensive study of anti-KLH serum antibody levels and B cellular kinetics in conjunction 
with the expressed variable and constant IgH sequence repertoire of KLHspec primary 
PB, secondary PB and mBC was conducted. Overall, this approach permitted unique 
insights into a specific B cell repertoire’s composition, diversity and dynamics. In the 
second part a thorough description of B cell and mBC distribution and related pheno-
type of the latter represents a systematic study of tissue-residing mBC and revealed 
some aspects worth further investigations.  
6.1 The serum and cellular response to KLH immunization  
This is the first study to document a detailed antibody response together with B cellu-
lar kinetics in conjunction with the molecular information of the expressed antigen-
specific Ig involved in responses to a primary immunization in human adults.  
Upon primary KLH immunization, specific antibody, PB and mBC responses were 
delayed and of lower magnitude compared with the response to KLH booster immun-
ization of the same individuals. This concurs with the widely accepted concept of pri-
mary and secondary immune responses, concluded from studies in animal models 
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and children (77, 188, 189). Further, these results affirm the differences in immune 
responses that relate to a pre-existing antigen-specific immune memory in contrast to 
a naïve immune system.  
Noteworthy is one specific report though, which showed that upon rabies immuniza-
tion in adults, PB in the naïve volunteer group appeared later in blood (peak at day 
10) than in the already immune group (peak at day 7) and were of lower frequency 
(63), which is in accordance with the previously described kinetics and concurs with 
our findings here. However, that study further found that IgM antibodies did not pre-
cede the appearance of IgG and IgA antibodies and therefore contrasts a prototypic 
primary immune responses, where IgM antibodies should precede the appearance of 
IgG antibodies. This deviating pattern was also observed in another KLH study con-
ducted in adults (190). Thus both of these studies are consistent with our observa-
tions here (section 5.1.2) suggesting that the immune history of an individual indeed 
affects primary immune response kinetics to hitherto un-encountered antigens.  
Another uncommented but notable finding of the previous rabies study, which we al-
so observed, is the frequent appearance of IgA antibodies and circulating IgApos PB 
upon primary parenteral immunization. This consistent parenteral IgA induction, most 
likely independent from participation of the mucosal immune system (Figure 5-9), 
suggests a certain underappreciated importance of serum IgA for systemic protection 
as indicated by studies analyzing parenteral influenza and pneumococcal immuniza-
tions in elderly people. In these studies, the lack of protection correlated with signifi-
cantly reduced IgA responses (191, 192). Admittedly, in contrast to our and the 
rabies study, which were pure parenteral immunizations, prior natural sensitization 
via mucosal surfaces is most likely in the case of pneumococcal and influenza im-
munizations/infections consequently potentially causing still pronounced IgA re-
sponses during re-challenges. At least, this would be consistent with results from a 
previous KLH study (193). In that study it was shown that primary intranasal KLH 
immunization primed the volunteers for strong IgA (but also IgG) serum responses to 
subsequent subcutaneous immunizations. In contrast, in our KLH study we detected 
a reduced serum IgA response upon the parenteral re-challenge.  
Unfortunately, we cannot deduce or test implications for immune protection or in-
flammation conferred by the anti-KLH IgA as one cannot “protect” an individual from 
KLH and test it. It should be pointed out though that selective IgA deficiency is a rela-
tively common primary immune deficiency in Caucasians remaining an inapparent to 
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only mild illness in approximately 50% of affected individuals. However, those who 
seek help often suffer from significant illness, including a high susceptibility to infec-
tions, autoimmune diseases and allergies (194-196) pointing towards complex regu-
latory mechanisms related to selective IgA absence. Taken together, these results 
suggest that future investigations of human protective immune responses and poten-
tial failure of those as well as “misguided” systemic immune responses (e.g. autoim-
munity) should include measurements of specific serum IgA antibodies 
supplementary to the IgG and IgM responses, which is so far not routinely done.  
6.1.1 Two blood antibody repertoires: the cellular and the serologic 
The IgH sequence analysis of circulating KLHspec PB detected a predominance of 
IgA-expressing PB which led to an interesting disparity to anti-KLH serum IgG to IgA 
ratios (Figure 5-8 B). Such discordances between the specific humoral immunity and 
the circulating PB and IgH gene repertoire, respectively, elicited by immunization 
have been described before (39, 197), while the underlying mechanisms remained 
unclear. One explanation is offered by the results from the oral immunization study 
from Czerkinsky and colleagues, in which it was demonstrated that the specific circu-
lating antibody-secreting cells did not contribute to an increase of specific serum an-
tibody levels while specific antibodies were found increased in saliva and tears. This 
suggests that the circulating PB were migrating to their designated survival or usage 
site to produce antibodies locally which did not emerge in the serum. In conse-
quence, circulating PB induced by systemic immunization might represent to the BM 
migrating cells, which may become main serum antibody producers only when estab-
lished in their niche.  
The underlying mechanisms determining which GC-derived PB is entitled to recircu-
late remain undefined. Also, whether IgA PB might either be more migratory-prone 
than IgG or IgM PB, or alternatively are generally sparse antibody producers com-
pared to the other two, or are less well accommodated in e.g. the BM niche com-
pared to IgG PC remains to be shown. The latter possibility might be supported by a 
recent study showing that the more mature CD19neg BM PC compartment holds more 
IgG than IgA PC whereof potential reasons remain to be elucidated (198).  
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Alternatively, at least for the primary response, the majority of serum IgM, IgG and 
IgA antibodies could be derived from unmutated extra-follicular short-lived PB/PC as 
first line of defense which have been described to be non-migratory (35).  
Anyhow, in line with the aforementioned KLH study (197), the circulating PB between 
days 14-18 would not be the major cellular correlates for the serum antibodies at that 
time point. Clarifying the raised possibilities here will require further studies address-
ing the circulatory and sessile tissue PB/PC compartments in conjunction with serum 
antibodies in more depth. In this regard, one study delineated the constituent anti-
bodies of the human serum IgG repertoire after vaccination and examined their rela-
tionship to the antibody variable gene repertoire encoded by circulating B cells. The 
results revealed the molecular composition and characteristics of the vaccine-specific 
serum antibody repertoire and demonstrated differences between the end-point re-
sponse (the serum antibodies after 9 months) and the day 7 peripheral PB (39). 
However, this study did not comment on chronological coinciding PB and serum anti-
body repertoires.  
6.1.2 Mechanistic insights through analysis of KLHspec IgH sequences 
Analysis of the expressed variable and constant IgH repertoire of KLHspec PB and 
mBC during the response allowed insights into the mechanism and composition of a 
human primary response repertoire. A detailed study of the sequences revealed that 
KLHspec B cell repertoires were far more diverse than previous studies suggested for 
primary responses in rodents (199-201). The diversity in the VH and JH segment us-
age together with the relatively broad CDRH3 length distribution were indicative of an 
unrestricted response, i.e. availability of diverse epitopes on KLH. Yet, in contrast to 
the extensive genetic diversity of available naïve B cell receptors, the VH-JH combina-
tions together with statistical estimations on the KLHspec PB repertoire sizes suggest-
ed a relatively small pool of involved clones, indicative of strong antigenic selection. 
This finding concurs with a previous report that showed that the complexity of the 
antigenic surface of tetanus toxoid also caused an unrestricted but selected B cell 
response (37). 
Alignment of VH and CDRH3 regions led to retrieval of clonally related expanded 
clusters of KLHspec B cells. We thereby found a within donor between day variation of 
the circulating primary KLHspec PB repertoires (Figure 5-17 B) suggesting that these 
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cells presumably left secondary lymphoid tissues to migrate via the blood stream to 
their potential survival niche, e.g. the BM (64, 78, 167, 198), which would be con-
sistent with the above mentioned PB migration hypothesis.  
In contrast to a previous study conducted in mice which showed a gradual increase 
of the SHM load of circulating PB/PC between day 7, 10, 14 and day 28 after primary 
immunization (64), we could not detect a steady axis of SHM increment in the prima-
ry circulating KLHspec PB although a principle repertoire turnover was detectable. 
Noteworthy is also our, so far in the literature not described, consistent observation 
that approximately one third of the primary specific PB exhibited high mutation fre-
quencies (further discussed below).  
6.1.3 A human B cell repertoire shift? 
Further very interesting findings were revealed when the clonal overlap between the 
KLHspec primary PB, mBC and secondary PB repertoires was investigated. Firstly, the 
presence of the yet few clonally-related primary and secondary PB sequences is a 
direct genetic measurement of mBC establishment and reactivation, which has been 
presumed from many previous studies but remained to be shown in humans until 
now.  
Secondly, only few clonal overlaps between the KLHspec primary PB, mBC and sec-
ondary PB repertoires were found. Moreover, the secondary PB pool appeared clon-
ally even more diverse than the primary PB pool with the emergence of largely new 
clones. This is intriguing as one would logically assume that prominent expanded 
clones observed in the primary PB pool would seed into the mBC pool and reappear 
upon its reactivation in response to immunization with the very same antigen. 
Yet, conform to our results, and although this finding is against expectations, this ob-
servation has been described in the murine system before by Berek and colleagues 
who referred to it as “repertoire shift” (41, 43, 202). With reference to their model an-
tigen oxazolone, Berek and Milstein speculated that the reason for this phenomenon 
may be firstly the higher affinity for the antigen of a canonical variable region combi-
nation (i.e. VH-Ox1) dominating the primary response and its high frequency in the 
naïve available repertoire. In contrast, the VHM21-Vκ-Ox1 variable region combina-
tion, which was an important component in their reported repertoire shift, had a much 
lower frequency in the pre-immunization repertoire. Speculating that during matura-
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tion of the primary response, certain clones will proliferate faster as they acquire ad-
vantageous mutations while others may fail to increase their affinity adequately, an 
initial advantage may not be of sufficient value in the longer term to successfully 
compete in the arising antigen-specific B cell pool.  
Our study extents this concept to humans and in a more real-life scenario of a matur-
ing primary and secondary response. The suggested scenario would offer an expla-
nation for the initial presence of extensively expanded KLHspec clonal families, some 
even with high mutation frequencies, of which the potential origin will be discussed 
below, that disappeared largely in the mBC repertoire and the secondary response, 
respectively.  
Additionally, the antibodies arising from the canonical activated primary clones will 
cover their epitopes on the antigen, which in consequence blocks the interaction of 
the (canonical combination) GC B cells and antigen-antibody complexes on the sur-
face of FDC. This would additionally give a competitive advantage to potentially low 
affinity (KLHspec) B cell clones recognizing different epitopes over time, which we may 
not have isolated during the time frame of our sampling but which may have seeded 
into the mBC pool. These possibilities remain unproven at this point but offer logical 
explanations as to why the mature response is distinct from the primary repertoire 
and more diverse in gene combinations, i.e. clones.  
Yet, an important aspect to point out is that it is unknown which proportion from the 
entirety of available antigen-specific cells is represented in peripheral blood and how 
well that pool mirrors the ongoing immunization-induced processes in lymphoid tis-
sues. That the circulating PB pool can only be a minor fraction of the entire available 
specific PB repertoire is apparent by the fact that the blood can only hold a small 
proportion of B cells at any time compared to spleen, BM and other lymphoid tissues 
as shown in this very study (section 5.2) and by others (203, 204). Results from a 
mouse study further showed that antigen-specific PB in blood exhibited delayed SHM 
load compared to splenic PB, but paralleling SHM load to that of BM PB/PC, support-
ing the notion, that the circulating compartment is established directly by blood-borne 
PB and secondly, suggests that analysis of circulating PB will lead to underestimation 
of affinity maturation processes still ongoing in GC within secondary lymphoid organs 
(64).  
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6.1.4 Origin of highly mutated KLHspec primary PB and potential under-
lying mechanisms 
As mentioned before, the analysis of IgH sequences from circulating primary KLHspec 
PB revealed a considerable proportion of cells with an unexpected high mutation load 
compared to, the only available data in this regard, primary immunization responses 
in rodents (45, 47, 62, 64, 82, 158, 162, 205-207). Based on the here presented cal-
culations of the theoretical underlying mutation rates required to generate such highly 
mutated VH genes from germline sequences and in due consideration of acknowl-
edged cell cycle durations and mutation rates, it appears unlikely that unmutated na-
ïve B cells can be the precursors of these early PB (described in section 5.1.12). 
Thus, alternative explanations have to be considered.  
Firstly, duration of cell division of human B cells could be considerably shorter than of 
murine B cells. Yet, this possibility appears unlikely since human embryonic stem 
cells, which are considered as very fast dividing cells, already require 16 hours (208) 
to complete one cycle while other human fast dividing cells are described to take 22-
24 hours and others even considerably longer (209). Besides, even if human GC B 
cells could take as little as 8 hours per division, as assumed in our calculations here, 
they would not constantly divide over the 14 to 18 days as at least selection has to 
intervene in between.  
Therefore, secondly, the mutation rate in humans could indeed be considerably high-
er than described for rodents. Yet, it needs emphasis that the SHM rate has profound 
consequences for the fate of mutating B cells, i.e. whereas low rates may fail to pro-
duce sufficient genetic variation for efficient affinity-based maturation, too high muta-
tion rates would lead to poor clonal expansion due to a high frequency of deleterious 
mutations. Therefore we can assume that the rate cannot exceed a certain value. In 
this regard, computer simulations found, with consideration of clonal expansion to-
gether with sufficient diversification both consistent with observed affinity maturation 
values, that the SHM rates would have to range optimally between 0.5-1.0x10-3 muta-
tions/bp/generation (210-212). These considerations appear also valid for humans.  
 
Therefore, I suggest a third possibility. I propose that the highly mutated primary 
KLHspec PB were descendants of presumably cross-reactive mBC. In contrast to chil-
dren and most laboratory rodents, human adults theoretically possess a B cell reper-
toire available for primary immune responses that comprises not only naïve B cells 
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but also a considerable population of mBC. The latter constitute approximately 15-
50% of the entire B cell compartment (Figure 5-24; (213)) and it would be unlikely 
and pose un-economical to reserve this repertoire only for the original inducing anti-
gens. An identifiable property of such a cross-reactive mBC recruitment would be the 
presence of highly mutated germline genes early in the response next to un- and low 
mutated ones, as evidently observed in the current KLH study. As such highly mutat-
ed B cell clones were not identified in primary responses in the murine system so far 
is this the first description of this phenomenon.  
In contrast, during secondary KLH immunization no unmutated KLHspec PB were ob-
served and even the lower mutated sequences could not be generated within 7 days, 
based on the same calculations as performed for the primary KLHspec PB (not 
shown). Hence, participation of presumably cross-reactive mBC in a primary re-
sponse may occur whereas, in accordance with the literature, the other way around, 
participation of naïve B cells in higher order responses is not indicated. Possible rea-
sons for that are likely based on out-competition of naïve B cells by mBC due to their 
increased frequencies and intrinsic properties, as reviewed elsewhere (214), as well 
as the presence of memory T cells in a primed system (215).  
Nevertheless, the proposed recruitment of cross-specific mBC in this primary re-
sponse did not result in kinetics characteristic of memory responses (77, 188). It is 
possible that the KLH-cross-reactive mBC were of such low frequency that their re-
sulting effector cells and antibodies were not detectable before day 10-14. Incon-
sistent with that suggestion is however that in 4 of the 5 donors pre-primary 
immunization circulating KLH-binding mBC frequencies ranged from 0.1% to 0.6% 
which is concurrent with described mBC frequencies of other antigen specificities, 
resulting in expected secondary response kinetics upon challenge (203, 216-218).  
Besides, it is unknown how many mBC are required to mount bona fide secondary 
responses. In this regard it has been indicated that as few as 25 mBC might be suffi-
cient (219), and these numbers were readily exceeded by the here identified blood 
KLH-binding mBC frequencies.  
Another possible explanation is that the potential activation of cross-reactive mBC 
has an altered pattern compared to mBC re-activation to their anamnestic antigen. 
Yet, reasons for this have to remain subject to speculation as this study did not ad-
dress the following possibilities in the experiments. It could be that mBC require in-
deed help from memory T cells to mount memory responses. A previous human KLH 
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study did not identify significant in vitro KLHspec (memory) T cell responses before 
KLH immunization in naïve donors (136). Hence, KLH-binding mBC would receive 
help from naïve but not memory T cells, consequently presumably leading to the ob-
served primary kinetics. In line with this suggestion, one study indicated that B cell re-
activation/GC participation is faster in the presence of pre-existing T cell help com-
pared to kinetics resulting from de novo development of helper T cells from naïve T 
cells (220). However, while it is generally acknowledged that T cell help is critical to 
the generation of B cell memory (221, 222), the principle requirement of T cell help 
for mBC (re-)activation remains unclear and is under current investigation. One re-
cent study in mice showed that IgM mBC do not depend on T cell help to generate 
antibodies while class-switched mBC did largely not generate antibody-secreting 
cells in absence of T cell help indicating that mBC greatly, although not absolutely 
depend on T cell help for their reactivation (154). In line, a study conducted with hu-
man mBC upon vaccination with a polysaccharide-conjugate vaccine highlighted a 
critical role of T cells in the differentiation of mBC into antibody-secreting cells (223). 
The here proposed mBC reactivation under absence of memory T helper cells could 
be consistent with these observations. However, other studies indicated that the ef-
fect of T cell depletion on generation of antibodies from mBC is only minimal and 
therefore T cell help for mBC activation would be dispensable (219, 224).  
Nevertheless, a consensus exists that mBC reactivation appears to require at least a 
specific microenvironment including interactions with other cells as previous experi-
ments demonstrated that homing of mBC to intact lymphoid follicle structures includ-
ing presence of FDC was a necessity for mBC reactivation (219, 225).  
In the present study, we may have observed tissue homing of the KLH-binding mBC 
as these cells were detectable in the periphery prior to primary immunization but not 
shortly afterwards followed by their later re-appearance. This suggests their recruit-
ment to lymphoid tissues and their temporary retention. Such specific immune re-
sponse-related lymphocyte behavior has been observed before. In few animal 
studies it was shown that pre-immunization circulating antigen-specific lymphocytes 
were reduced in the periphery by antigen injection presumably due to their temporary 
retention in secondary lymphoid organs (226-228) and one study conducted in hu-
mans reported reduction of circulating B and T cell numbers 7 to 14 days after yellow 
fever vaccination and their recovery to baseline levels afterwards (229). The time 
frame of lymphocyte disappearance and re-appearance of the latter study is indeed 
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consistent with the disappearance and re-appearance kinetics of the KLHspec mBC in 
the current study. 
In this regard another observation deserves attention. As can be seen in Figure 5-6, 
the pre-primary immunization KLH-binding mBC were poorly blockable which yet did 
not constitute mere unspecific background as such background should remain stable 
over time. Instead, the observation was that subsequently the KLH-binding mBC 
were decreased as described above and the later re-appearing well blockable     
KLHspec mBC did not add on top of these pre-immunization mBC frequencies. To-
gether with their blood appearance kinetics, this suggests that the pre-immunization 
KLH-binding mBC were not only retained in secondary lymphoid organs but under-
went maturation and selection. Supposedly, in this process low affine mBC, con-
sistent with poor blocking efficiency, either increased their affinity or were negatively 
selected from the repertoire. 
I will close this part of the discussion by returning to a point raised earlier. Theoreti-
cally, every large protein antigen, including self-antigens, can be recognized by a 
specific BCR. It follows that BCR from mBC are not excluded. As poly- and auto-
reactivity appear to be not specifically counter selected in the mBC generation during 
a GC reaction (230-233), likely due to low abundance or unexpressed self-antigen in 
close proximity to the GC environment (234), there must be a mechanism preventing 
those mBC’s uncontrolled reactivation. Otherwise, if mBC acted without such licens-
ing in vivo, the associated uncontrolled mBC response would facilitate the initiation, 
diversification and establishment of long-lived auto-antibody responses as soon as 
their cross-reactive auto-antigen becomes available through cell rupture or other inci-
dences. Thus, in the framework of autoimmunity the potential mechanism(s) control-
ling such unrestricted recruitment and activation of cross-specific mBC requires 
future attention and investigation. 
6.2 Tissue distribution of mBC 
The second part of this study describes the distribution and compartmentalization of 
human mBC within different lymphoid organs and the related phenotype compared to 
in blood circulating mBC. General B and T lymphocyte subset compositions indicated 
an organ and blood specific compartmentalization of both lineages that was in ac-
cordance with a previous study (177). Tissue-dependent compartmentalization was 
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revealed to be further evident on the B cell subset level, with subsets exclusively pre-
sent in the one or other organ. Thereby, (CD19pos)CD20negCD27neg B cells exclusive-
ly found in the BM presumably constitute a pre-mature B cell population as CD19 
represents the earliest B cell lineage determinant and the expression of other B cell-
lineage antigens follows thereafter (235). The identity of the in BM found 
CD20negCD27pos B cells has to remain elusive at this point but future studies address-
ing their state of Ig diversification and their stimulatory potential may assist in clarify-
ing their origin.  
On the other hand, CD20posCD27neg (naïve) B cells were always abundantly present 
in every tissue. Yet in the spleen they were outnumbered by CD20posCD27pos B cells 
(mBC). In this regard, analyses of mBC in the organs revealed that these cells did not 
simply correlate with the relative distribution of CD19pos B cells but showed enrich-
ment in the spleen followed by tonsil. Previous studies described the presence of 
mBC in the spleen (99, 104, 106), tonsil (101, 106, 236, 237) and BM (96) but a 
comparable and comprehensive analysis of these was not conducted.  
Interestingly, the current study found no indication of any correlation of age to mBC-
accumulation in adult lymphoid organs. This suggests that the diverse lifestyles, im-
mune history and genetic heterogeneity within the here representative analyzed do-
nor population did not result in large variations of mBC content in the respective 
organ over time. Moreover, together with the results from the absolute number ap-
proximations, each tissue/organ appears to have a certain pre-defined capacity to 
maintain B cells and mBC. Such notable consistencies have been identified before 
for human T cells (177).  
Unfortunately we did not have access to tissue samples from younger children, which 
should however be addressed in future studies as especially the mBC compartment 
is established during the first 10-15 years of life, as mentioned before (section 5.2.4). 
It would be interesting to determine the accumulation of mBC during these years in 
the one or other organ and correlate that to potential effects of responsiveness to 
vaccination and to the potential to establish long lasting antibody titers. It has been 
shown that the splenic marginal zone which accommodates IgDpos mBC in its majori-
ty but also IgDneg mBC requires development over the first 2 years of life which is cor-
related with a lack of response to polysaccharide vaccines and a high incidence of 
encapsulated bacterial infections (108, 182).  
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Notably, also for the BM PC niche a certain requirement of development is indicated 
since early life TD antibody responses are characterized by a rapid decline of serum 
titers, such that antigen-specific IgG antibodies revert to baseline levels within 
months following infant immunization (238). It has been speculated that early-life BM 
stromal cells fail to provide the molecular signals that support PB survival and differ-
entiation into surviving PC (239). Nevertheless, as conjugate vaccines and other TD 
immunization are functional in children and induce at least a reactive B cell memory, 
i.e. mBC, even when antibody titers constantly decline, we can assume that the clas-
sical mBC’s survival and/or maintenance differs from the other two either in location, 
micro-environmental factors or in the principle requirement of a certain survival niche 
(240). 
6.2.1 Phenotype of tissue-residing mBC 
The overall mBC phenotype analysis conducted here (Figure 5-31) found that blood 
and splenic, BM and tonsillar mBC were largely similar in most of the markers ana-
lyzed. Yet, some differences identified in the isotype distribution, CD69, CD62L and 
β7 integrin expression leave room for speculation on mBC subset homing behavior 
and tissue residency.  
Firstly, a certain tissue-intrinsic compartmentalization of the different isotype-specific 
mBC pools was detectable. Tonsillar mBC showed a relative enrichment of IgApos 
and IgGpos cells as compared to spleen, BM and blood and a reduced presence or 
even de-enrichment of double-positive mBC. This may reflect the different functions 
of the tonsils as part of the mucosa-associated immune system and/or may be the 
result of the recurrent bacterial infections, as cause of the tonsillectomy. Yet, tonsillis-
tis is usually caused by streptococcus or pneumococcus infections for which 
IgDposCD27pos mBC were shown to specifically impart the protective immune re-
sponse (241) and from that one would expect an accumulation of these cells in the 
tonsils. However, as it is in principle possible that such initial TI responses convert to 
TD responses including switching to IgA or IgG then this would be consistent with the 
here found results again. To address this further, subsequent experiments should 
include detailed BCR sequence analyses to elucidate consequent resulting interrela-
tionships between the pre- and post-switch tonsillar mBC compartments, besides 
determination of their specificities. 
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Another very interesting observation was that tonsillar mBC expressed the lympho-
cyte mucosal homing associated molecule β7 integrin less frequently compared to 
splenic mBC for example. It has been shown that recirculation of murine lymphocytes 
to the mucosae involves binding of α4β7 integrin to the mucosal vascular addressin 
cell adhesion molecule 1 (MAdCAM-1), which is predominantly expressed on venules 
in the gut-associated lymphoid tissue (GALT) and intestinal lamina propria (242). In 
humans there is only indirect evidence suggesting that α4β7 expressing (T) lympho-
cytes migrate selectively to the intestine and that it is a ligand for MAdCAM-1 (243-
245) while it is generally accepted that α4β7 integrin is involved in lymphocyte muco-
sal homing behavior and mucosa-associated responses (152). The infrequent ex-
pression of β7 integrin by mBC in a mucosa-associated organ, i.e. tonsil, and the role 
of β7 integrin on splenic mBC in such abundance pose an interesting finding and 
suggests for the latter either their gut mucosal origin or their potential of re-circulation 
to the gut mucosal tissues.  
In mice, it was shown that a splenic side population seeded into the gut and was re-
sponsible to replenish the intestinal B1 B cells pool (246) illustrating that splenic B 
cells (precursors) can seed into the gut B cell pool. For the human system, based on 
the following indications, I put forward the hypothesis that splenic marginal zone 
(IgDpos) mBC, which are thought to confer protection from bacterial infections, may 
even traffic between the gut mucosae and the spleen presumably via the blood. In 
humans MAdCAM-1-expressing fibroblasts draw a ring like structure within the hu-
man splenic marginal zone (107) which I propose may specifically retard the CD27pos 
mBC in this area. This suggestion would be consistent with the observation that the 
human splenic marginal zone exhibits an accumulation of IgDpos mBC which I could 
show here possess a higher density of β7 integrin than IgDneg mBC (Figure 5-32). 
The proposed gut-spleen interrelation could consequently induce a systemic protec-
tion to gut-originating pathogens. This may prove vital in the case of mucosal barrier 
damage and pathogen leakage into the blood stream.  
That an exchange of marginal zone and gut B cells can principally occur is evident by 
the fact that MALT lymphomas frequently populate the splenic marginal zone (shortly 
summarized by Jo Spencer (247)). 
Strikingly, MAdCAM-1 expression is completely absent in human tonsils (245).  
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Another noticeable finding was revealed when analyzing expression of CD69 and 
CD62L. MBC from tonsils expressed low levels of CD69 contrasting circulating, 
splenic and BM mBC in which CD69 expression was absent. CD69 is an acknowl-
edged marker of early (T) cell activation which consequently should coincide with 
proliferation (248). As the here conducted analysis of the cell-proliferation marker Ki-
67 showed that mBC from all tissues were quiescent cells in their large majority, we 
can assume that CD69 does not mark an activated mBC population within the tonsil. 
Therefore a second function of CD69 expression may be of interest here. CD69 has 
been indicated to have a potential role in thymocyte egress and lymphocyte migration 
(249). In this regard, Shiow and colleagues further showed that CD69 negatively reg-
ulates S1PR1 surface expression and consequently hinders lymphocyte tissue 
egress (250). Specifically, tissue resident memory T cells populations (TRM) have 
been found to lack expression of the transcription factor Krüppel-like Factor 2 (KLF2) 
and its target S1PR1 whereof in consequence surface expression of CD69 is elevat-
ed and this expression has been linked to their retention (251-256). With regard to B 
cells, direct cell surface staining of S1PR1 on B cells has proven difficult (257) but 
elevated CD69 expression can serve as a surrogate marker for its reduced expres-
sion (258, 259). Therefore, the here found CD69pos tonsillar mBC could constitute a 
true tissue-resident mBC subset in contrast to BM and splenic mBC. Noteworthy 
though, CD62L has also been shown to be under positive control of KLF2, i.e. upreg-
ulation of CD69 should coincide with a loss or at least a strong reduction of CD62L 
surface expression (260) and consistently TRM do not express it anymore. In this 
study we found an interesting variability of CD62L expression on human tissue-
residing mBC not consistent with this just described CD69-CD62L counter-
expression described for TRM. As expected CD62L was highly expressed on circulat-
ing mBC and a marginal but significant reduction was detectable on BM and tonsillar 
mBC. For the latter, the still high abundance of CD62L is not consistent with proper-
ties described for tissue-resident cells. Yet, at least for mouse B cells, regulation of 
trafficking-associated molecules under KLF2 appears distinct compared to T cells 
(259-261) whereas these aspects require clarification in the human system.  
However, CD62L was strongly reduced on splenic mBC which poses an interesting 
discrepancy. Upon CD62L engagement, e.g. entry into a lymph node, the molecule is 
normally shedded. However, migration or rather recirculation through the spleen has 
been shown to be independent of CD62L (262, 263) which is why it should not have 
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been shedded on the recirculating splenic mBC populations which essentially should 
resemble blood mBC in this regard. Although the level of expression might not essen-
tially be related with the functional capacity, as e.g. known for CXCR4 expression 
levels and the resultant migratory capacity towards CXCL12 (78, 186), the strong 
reduction to absence of CD62L on the supposedly recirculatory mBC populations in 
the spleen was not expected (182) and the underlying mechanisms require future 
investigations.  
Albeit absence/low concentration of CD62L, in further support of a recirculatory na-
ture of splenic mBC is the here reported finding that splenectomy reduced peripheral 
blood mBC frequencies (Figure 5-35). This is also in accordance with results from 
other investigations (108-110). And notably, this contrasts the ineffectual absence of 
tonsils on circulating mBC proportions, which is its notable first description to the best 
of our knowledge. Thus, the here described CD69pos tonsillar mBC do not appear to 
contribute to the circulatory pool and therefore may indeed constitute a tissue resi-
dent mBC pool.  
To address tissue-residency versus circulatory behavior of (memory) B cells in the 
human system from a more functional angle, current biopharmaceutical therapies 
may be of assistance. It is acknowledged that B cell depletion during therapy with the 
anti-CD20 antibody rituximab requires recirculation of affected B cells since the liver 
has been identified as the major site for the cell depletion (264). Therefore, studies 
addressing the B cell depletion status in different tissues can serve as an indicator for 
the resident versus circulatory nature of the organ’s (memory) B cell populations. Un-
fortunately, such studies are only scarcely available for humans. Few studies could 
show that rituximab largely depletes splenic CD20pos B cells (70, 265, 266) consistent 
with their suggested recirculatory nature, mature B cells in BM (265, 267, 268) and 
largely also in lymph nodes (269). In contrast, B cells resident in the GALT tissues 
appear resistant to rituximab treatment (270). However, no such data is available for 
human tonsils and therefore final conclusions on tissue-resident mBC in tonsils can-
not be drawn at this point.  
We reported on a splenectomized patient that provided instructive data exhibiting a 
normal B cell memory recall response to TT immunization despite having undergone 
splenectomy 13 years previously, was not booster immunized in between and subse-
quently required 3 treatment cycles with rituximab because of refractory ITP (203), 
but was B cell-repleted when we immunized her. Although this is only a one case 
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report, it indicates that even when the entire circulating mBC compartment was elimi-
nated and the spleen absent, which holds the largest (TTpos) mBC population (section 
5.2.8) there must be a compartment of mBC surviving elsewhere. This conclusion 
would be consistent with publications by Gowans and colleagues where it was de-
scribed that cannulation and drainage of the rat thoraic duct for several days was as-
sociated with progressive decrease of lymphocytes in the lymph, lymph nodes and 
spleen (271). In extension of these experiments they showed that depletion of these 
circulating lymphocytes prior to booster immunization did not affect a secondary re-
sponse (272) suggesting that the sessile lymphocyte compartments were the re-
sponse eliciting ones.  
Potential sites offering mBC survival niches are the mucosal/intestinal tissues, the 
skin or other non-lymphoid tissues, as shown for TRM. Or even the tonsil, as dis-
cussed above. Notably, the tonsil was found to contain TTpos mBC. Since an experi-
ment demonstrated that parenteral TT immunization did not induce local responses in 
tonsils at all (273), these mBC must have migrated there from their site of induction 
but may not seed back into recirculation which however remains to be determined.  
The presence of mBC, and even of TTpos mBC, continuously circulating in peripheral 
blood indicates that a certain mBC pool constantly patrols the body. Yet, the relation-
ship to tissue-residing mBC and whether there is a constant turnover has to remain 
unclear at this point.  
The discussed aspects raise important questions and contradictions which are 
worthwhile addressing in future studies to clarify the existence, whereabouts and re-
quirements of potential tissue-resident human mBC and their regulation in support of 
development of long-lasting immunity induced by vaccines but also for immunothera-
pies targeting pathogenic mBC.  
6.3 Outlook and concluding remarks 
This study contributes to our understanding of human B cell memory induction, 
maintenance and reactivation. Nevertheless open questions remain and even new 
questions arose. To start with, the results presented in the KLH immunization study 
should be confirmed by experiments using a different primary immunization, whereby 
e.g. yellow fever, tick-borne encephalitis or hepatitis B immunizations would be can-
didates. In such experiments the data collection should be expanded though.  
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Firstly, to address the question whether mBC, specific to originally unrelated anti-
gens, are cross-recruited into such a (primary) immune response based on binding of 
their BCR to the new (immunizing) antigen, isolation and BCR sequencing of pre-
immunization antigen-binding mBC should be performed.  
Secondly, in addition, also pre-immunization bulk naïve B cell and pre- and post-
switch mBC populations should be FACS sorted and their BCR repertoire sequenced 
using a next-generation sequencing approach, as described and performed for other 
problems before (39, 156, 274). These sequences could be subsequently investigat-
ed for their relationships with the later in blood appearing immunizing-antigen-specific 
PB and mBC. In addition, the antigen-specific B cell populations should be monitored 
longer, including sorting and sequencing, which could assist in clarifying whether the 
proposed repertoire shift already occurs late in the primary response or upon recall, 
provided that this is visible in the circulating B cell populations.  
The suggested experiments could also contribute to an understanding of whether 
different mBC layers existed in humans which however would include also sorting 
and sequencing experiments prior to the secondary immunization. Another aspect of 
major importance is the monitoring of T cells in such a response and to define, if pre-
sent or absent, how (cross-specific) memory T cell help can influence primary im-
mune responses in humans. Detection of antigen-specific T cells can be performed 
by in vitro stimulation of PBMC with the antigen and detection, characterization and 
enumeration of CD154pos T cells, i.e. antigen-specific cells, several hours afterwards 
(275, 276). In a broader sense such knowledge may help optimizing vaccination 
strategies and could also contribute to an enhanced understanding of underlying 
mechanisms involved in autoimmunity.  
The data of this thesis further provide an assessment of human mBC distribution and 
characteristics, including defined antigen-specific (TTpos) mBC. Beyond their identifi-
cation and characterization, it is unclear if these mBC share the same molecular and 
functional characteristics. To address this, investigations of tissue-residing mBC pop-
ulations (IgGpos versus IgApos versus IgMpos/IgDpos) should be extended to more tis-
sues, e.g. skin, intestine and lymph nodes. Also such a new study should include 
sorting of the different mBC populations and subsequent BCR sequencing as only 
such an approach could grant insights into mBC repertoire relationships between the 
different tissues and also to blood mBC. However, a concern here is that since BCR 
repertoires vary considerably between individuals, to generate interpretable results, 
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such a comparative analysis would have to be performed on mBC isolated from tis-
sues from one donor, e.g. from organ donors, which may pose ethically difficult. Al-
ternatively, matched blood-tissue samples could be used however, that approach 
would have obvious limitations. Yet, an experiment which could be performed is the 
sorting and sequencing of mBC populations within an organ which also has not been 
performed so far but could contribute clarification to the debate of the relationships of 
IgDneg and IgDpos mBC (277). 
Finally, the BM has been known to provide niche conditions supporting the survival of 
antibody-secreting PC and also for memory T cells. As quiescence in terms of prolif-
eration and activation appears a favorable condition to sustain also reactive memory 
lymphocytes, since a frequent reactivation could cause their exhaustion or extermi-
nate them from the repertoire, the non-inflammatory environment together with the 
niche conditions provided would make the BM an ideal tissue for memory lymphocyte 
maintenance. Yet, the here described features of tissue mBC do not suggest that 
these are preferentially maintained in the BM, in contrast to memory T cells and long-
lived PC. Hence, future exploration of this aspect is of importance as knowledge 
about human mBC maintenance and survival requirements could be used for devel-
opment of new vaccination but also therapeutic intervention strategies. 
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8. Abbreviations 
Abbreviation Meaning 
% Percent 
°C Degree centigrade 
µ Micro 
aDigFITC Digoxigenin-specific FITC-labeled F(ab)2  
AID Activation induced deaminase 
APC Allophycocyanin 
APC-H7 Allophycocyanin-HiLyteFluorTM750Bis-NHS-ester 
BCR B cell receptor 
BD Becton Dickinson 
BM Bone marrow 
bp Base pair 
BSA Albumin, Bovine Fraction V  
Cµ Ig mu constant heavy chain region 
Ca1 Ig alpha-1 constant heavy chain region 
CB Centroblast(s) 
CD Cluster of differentiation 
cDNA Complementary deoxyribonucleic acid 
CDR Complementary determining region 
CDRH CDR from IgH chain 
Cg Ig gamma constant heavy chain region 
CH Constant heavy 
CSR Class switch recombination 
Cy Cyanine 
d Day 
D Diversity heavy chain segment 
DAPI 4,6 diamidino-2-phenylindole 
DC Dendritic cell 
Dig Digoxigenin 
DNA Deoxyribonucleic acid 
dNTP Deoxy-nucleotide-triphosphate 
DTT Dithiothreitol 
DZ Dark zone 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme Linked Immunosorbent assay  
ELISpot Enzyme-linked immunospot assay  
FACS Fluorescence activated cell sorting  
FCS Fetal calf serum 
FDC Follicular dendritic cell 
FITC Fluorescein isothiocyanate 
FWR Framework region 
g Gram 
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GALT Gut-associated lymphatic tissue 
GC Germinal centre 
HD Healthy volunteer 
HIV Human immunodeficiency virus 
HLA-DR Human leucocyte antigen DR 
hrs Hours 
i.d. Intradermally  
ICOS Inducible costimulator 
ICOSL Inducible costimulator ligand 
Ig Immunoglobulin 
IgA, IgD, IgE, IgG, IgM Ig isotype A, D, E, G or M 
IgH Ig heavy chain 
IgL Ig light chain 
int Intermediate 
ITP Immune thrombocytopenia 
JH Joining heavy 
Jκ Joining kappa 
Jλ Joining lambda 
KLF2 Krüppel-like Factor 2 
KLH Keyhole Limpet Hemocyanin 
KLH-Cy5 KLH labeled with Cy5 
KLH-Dig KLH labeled with Dig 
KLHspec KLH-specific 
L Liter 
LN Lymph node(s) 
LZ Light zone 
m Milli 
M Molarity 
MAdCAM-1 Mucosal vascular addressin cell adhesion molecule 1 
mBC Memory B cell(s) 
MFI Median fluorescence intensity 
MgCl2 Magnesium dichloride 
MHC Major histocompatibility complex 
min Minute(s) 
MNC Mononuclear cells 
mRNA Messenger ribonucleic acid 
n Nano 
n/a Not applicable 
NaCl Sodium chloride 
Neg Negative 
p Pico 
PacB Pacific Blue 
PacO Pacific Orange 
PAMP Pathogen-associated molecular pattern 
PB Plasmablast(s) 
PBMC Peripheral blood mononuclear cells 
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PBS Phosphate buffered saline 
PC Plasma cell(s) 
PCR Polymerase chain reaction 
PE Phycoerythrin 
PE-Cy7 Phycoerythrin-Cyanine7 
PerCp Peridinin-chlorophyll-protein complex  
Pos Positive 
PRR pattern recognition receptors 
R Replacement mutation 
RNA Ribonucleic acid 
RSS Recombiantion signal sequence 
RT Room temperature 
RT-PCR Reverse transcription polymerase chain reaction 
S Silent mutation 
s.c. Subcutaneously  
S1/S2/S3/S4/S5/S6 Splenectomized patient 1, 2, 3, 4, 5 or 6 
S1PR1 Sphingosine-1-phosphate receptor 1  
sec Second 
SHM Somatic hypermutation 
T Thymus 
Taq Thermus aquaticus 
TBE Tris-borate-EDTA  
TCR T cell receptor 
TD T cell-dependent 
TFH T follicular helper cells  
TI T cell-independent 
TRM Tissue resident memory T cells 
TT Tetanus toxoid 
TT-Cy5 TT labeled with Cy5 
TX Tonsillectomized HD 
UV Ultra violet 
V Volume 
VH Variable heavy  
Vκ Variable kappa 
Vλ Variable lambda 
VL Variable light  
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